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1 Introduction and outline of the thesis

1.1 Introduction and outline of the thesis
As coronary angiography (CAG) became widely practiced in 1960s, it was soon apparent 
that not all patients with clinical suspicion of coronary artery disease had obstruction 
of epicardial coronary arteries. It became clear that many patients showed no evidence 
of obstructive coronary artery disease. These observations were confirmed in larger 
studies, reporting that up to 20% of the patients, undergoing CAG, had no significant 
stenosis of the epicardial coronary arteries (1-3). Association with myocardial ischemia, 
however, remained a possible explanation for the angina, because sometimes it is the 
abnormal noninvasive test, which leads to the performance of a CAG. This is also 
the case in a patient with cardiac syndrome X (CSX), participating in the studies as 
described in this thesis.
Case study
A school teacher, age 53, married and two children, was referred because of dyspnoe 
and severe chest pains during exercise. These complaints started after an episode of fever, 
presumably due to an upper airway infection. She never experienced chest pains before, 
although she was used to running on a weekly basis (10 km in 1 hour). She consulted 
a pulmonologist, who found no explanation for the complaints. The X-thorax and a 
ventilation perfusion scan showed no abnormalities. 
During a holiday with her family, the chest pains returned, especially during exercise. 
She was no longer able to climb hills. Back home, her general practioner described 
nitroglycerin, which relieved the chest pains.
The patient had no cardiac risk factors. Physical examination by a cardiologist was 
completely normal, as were the routine laboratory test. The resting ECG was normal, 
during exercise, however, a significant ST-segment depression was documented and the 
patient again had angina-like chest pain. Myocardial 99mTc-MIBI perfusion SPECT studies 
during rest and exercise demonstrated a reversible perfusion defect in de anterior mid 
and anteroseptal mid segments (Fig 1), compatible with ischemia in the LAD region. A 
CAG was scheduled and a calcium antagonist (Tildiem) was prescribed. Angina symptoms 
decreased after tildiem (Fig 2).
In many other CSX patients, the effects of the usual anti-anginal medication are less 
or inconsistent. Reassurance is important but cannot always prevent emergency room 
evaluations and repeated catheterizations, with obvious effects on quality of life and 
health care costs, which according to the Women’s Ischaemia Syndrome Evaluation 
(WISE) study might be $ 1 million for each CSX patient in the USA. CSX therefore 
is an important health care problem which needs further study, with regard to the 
epidemiology, the pathogenesis, the diagnosis and prognosis in CSX patients (4). 
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Fig 2: Coronary 
angiography shows a 
normal left coronary artery
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Fig 1: Reversible perfusion defect anteroseptal mid and anterior mid.
1.2. Pathogenesis of cardiac syndrome X
Coronary microvascular dysfunction 
Coronary microvascular dysfunction (CMVD) has been suggested as the cause of angina 
in a subgroup of CSX patients with reduced CFR and normal coronary arteries (5). 
Coronary blood flow (CBF) abnormalities related to CMVD may differ substantially from 
those caused by flow-limiting stenoses in large coronary arteries detected by CAG. 
(fig 3) In the latter case, the impairment of myocardial perfusion is homogeneously 
distributed within the myocardial layers perfused by the stenosed artery resulting in 
detectable segmental perfusion defect.
In contrast, in the case of CMVD, the abnormality may not involve all coronary 
microvessels of a major coronary branch uniformly but may be distributed in the 
myocardium in a scattered manner as proposed by Maseri (6). This distribution of focal 
ischaemia in relatively small myocardial regions can provide a plausible explanation 
for the difficulties in obtaining objective evidence of myocardial ischemia in most CSX 
patients when standard diagnostic methods are used.
Hence, diagnostic tests evaluate different functional and anatomical aspects of the 
heart, the CAG is the gold standard test for evaluation of the coronary arteries but 
cannot detect microvascular dysfunction. On the contrary, imaging techniques like 
CMR and SPECT evaluate left ventricular myocardial blood flow, which is downstream 
of obstructive CAD and microvascular dysfunction. The subendocardium is most 
susceptible to perfusion impairment and ischaemia occurs in the subendocardium 
before advancing to the subepicardial layer. Subendocardial perfusion imaging may 
therefore be an important technique to enhance the sensitivity for detection of 
myocardial ischaemia.
Positron emission tomography (PET) provided evidence for a reduced coronary 
vasodilatation and myocardial ischaemia in CSX (7, 8), these results however could not 
be confirmed by others (9, 10). Similar disagreements occur for functional ischaemia 
during stress (11). 
A number of CMR studies have reported that abnormalities in the function and structure 
of the coronary microcirculation occur in many clinical conditions, including CSX. An 
important CMR study suggested the presence of subendocardial hypoperfusion (12) 
in 20 cardiac syndrome X patients stressed with adenosine. These results suggest a 
dysfunction of the coronary microcirculation.
Endothelial dysfunction might also be induced by mental stress, anxiety and panic 
disorders. Mental stress has been linked with impaired myocardial blood flow, 
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particularly in the microvascular bed (13, 14). Mental stress can cause vasoconstriction 
in patients without coronary disease, as in the case of CSX (15, 16).  Increased cardiac 
adrenergic activity can play a significant pathogenetic role in patients with CSX. 
Severe global or regional abnormalities in cardiac adrenergic innervation are indeed 
detectable in most patients and can favor coronary microvascular constriction. Other 
potential causes of coronary microvascular dysfunction, reported in several studies, 
include increased insulin resistance (17), which may facilitate endothelial activation and 
dysfunction, estrogen deficiency in women (18), enhanced activity of the membrane 
sodium-hydrogen exchanger (19), systemic inflammation (20-22) and coronary small 
vessel viral infection (23).
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Fig 3 In the case of an epicardial (Epi) stenosis, myocardial ischemia diffusely involves the whole 
myocardial (usually subendocardial) territory supplied by the vessel (gray area). In the case of 
microvascular alterations, myocardial ischemia is likely localized only in small myocardial areas, 
patchy diffused in the myocardium (small circles); territory. Also in this case, ischemia more easily 
occurs in subendocardial regions (more intense gray color of the small ischemic areas). Endo 
indicates endocardial. a and b indicate dysfunctional microvessels; P1 and P2, blood pressure 
proximal and distal to obstructive vessels
Reproduced with permission of Circulation
Fig 3: Differences in myocardial ischemia caused by a significant coronary stenosis (A) or by 
CMVD (B)
Abnormal pain perception 
Rosen and Camici studied angina pectoris as a model of visceral pain using PET and 
15O- labeled water for activation studies during pharmacologically-induced ischaemia 
(24). They obtained a ‘map’ of cortical activations involved in the perception of angina. 
Subsequently the difference between painful and silent myocardial ischaemia was 
investigated (25). It was concluded an abnormal handling of afferent signals by the 
central nervous system might determine the perception of cardiac pain and provide an 
explanation for CSX.
In addition, changes in regional cerebral blood flow during dobutamine stress were 
studied (26).  The CSX patients and normal controls had comparable responses to 
dobutamine, with activations in the hypothalamus, the thalamus, the right frontal cortex 
and the anterior temporal poles. These responses were associated with the sensation of 
a fast and powerful heartbeat. In CSX the dobutamine stress also generated chest pain, 
accompanied by activation in the right anterior insula.
Other studies, using neuromodulation devices (27), spinal cord stimulation (28) and 
autogenic training - an hypnosis-based relaxation technique (29) - have also suggested 
that CSX patients have an increased sensitivity to pain.
In summary, several potential causes of coronary microvascular dysfunction have been 
described, suggesting different, and variously concurrent, pathogenetic mechanisms 
in individual patients, which can also account for the described heterogeneous 
pathophysiological features of CSX. Accordingly, it is important to distinguish the 
syndrome from microvascular dysfunction in association with cardiac or systemic 
diseases, which can be defined as secondary microvascular angina (MVA) (5). Lanza 
have recently proposed a new classification of coronary microvascular dysfunction. He 
suggest to label CSX in the future as stable primary MVA (22).  
1.3 CSX Diagnosis
The definition of CSX is controversial. Literature reviews usually refer to the classic triple 
combination of angina pectoris, a normal CAG and noninvasive tests indicating the 
presence of ischemia. However, intervention CSX studies do not always stick to this 
classic triple combination. Also important cardiac textbooks like Braunwald describes CSX 
as the syndrome of only angina and normal CAG (“broad diagnosis”) (30). Furthermore, 
rheumatologic disorders, such as fibromyalgia and costochrondritis, and noncardiac 
causes of chest pain, such as esophageal dysfunction, have to be excluded as CSX.
The different set of criteria for CSX diagnosis may reflect the heterogeneity of the CSX 
group.
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The largest studies of test characteristics like sensitivity and specificity have been done 
with gated SPECT. The inter- and intra-observer agreements for SPECT on a large group 
of patients (n = 138) were 89% and 94%, respectively, employing three experienced 
readers (31). Another large study (n=108) gave good-to-excellent inter- and intra-
observer agreement, with kappa = 0.71 - 0.85 (32).
For CMR the inter- and intra-observer agreement for quantification as been assessed 
as 55% and 85%, respectively, but the inter-observer agreement improved to 88% 
when the poor-quality measurements were excluded (48 out of 160 segments (33). 
Interstudy variability for CMR of 15% was reported.(34). A Dobutamine CMR study 
with 19 patients showed inter-observer variability between individual and consensus 
interpretations, with kappa = 0.81 and kappa = 0.70 for wall motion and perfusion, 
respectively (35).
SPECT and first-pass perfusion CMR results compare favorably with those from 
ergometric tests. Most SPECT results have a diagnostic specificity close to 90% (32, 
36-38). Ergometric test results have a specificity of no more than 85%, and sometimes 
much less (30, 39).
Furthermore, the accuracy of the exercise-induced ST segment depression for detection 
of significant obstructive CAD is less for women than for men (30). Hence, CSX 
diagnosis may also be more difficult for female patients. In the United Kingdom a 
new guideline called “Chest pain or discomfort of recent onset” has been adopted by 
the NICE (National Clinical Guidelines Centre for Acute and Chronic Conditions). This 
recently adopted NICE guideline gives a negative advice on using the stress-ECG for 
women, owing to its poor sensitivity or difficulties in interpretation. 
This new guideline omits the exercise stress test from its diagnostic flowchart. Instead, 
it advises a calcium score for low pre-test likelihood; an MPS with SPECT/stress 
echocardiography/first-pass CMR for moderate pre-test likelihood; and an effectively 
immediate CAG for high pre-test likelihood (40). 
Owing to these test characteristics, there will be angina patients with a false-positive 
non-invasive imaging test and normal coronary arteries (labeled as CSX). On the other 
hand, some angina pectoris patients will have a false-negative diagnostic imaging test 
and are at risk for incorrect diagnosis ‘non-cardiac chest pain’.  Combining two tests, 
for example exercise stress testing in combination with SPECT may reduce the false 
negative rate.
Not only the aforementioned imaging techniques have shortcomings, also observer 
agreement on angina and CAG interpretation can vary from moderate to excellent 
(41). The inter- and intra-observer variations for CAG have been specified as 6% and 
14
7%, respectively (42, 43). We have also measured this variation using CAGs from the 
Spaarne Hospital Heemstede. It is noteworthy that 24% of the reinspected CAGs 
originally classed as normal were found to show up to 50% luminal stenosis. This 
discrepancy is partly due to how the CAG results were described: e.g. some observers 
classified patients with artery wall irregularities as normal. Overall, the agreement 
about CAG films showing significant stenosis was 100%.  
1.4 Gender differences and prevalence
The first CSX report by Likoff (1967) included only women with chest pain, positive 
exercise stress test and normal coronary arteries (44). 
Since then it remains stated that the majority of CSX patients are women (45, 46) .
In addition, gender differences exist in the clinical presentation of ischaemic heart 
disease. One systematic review and meta-analysis on the prevalence of angina in 
women versus men across 31 countries found that women had a slightly higher 
prevalence of angina compared with men. Angina prevalence using the standardized 
7-item Rose angina questionnaire, varied widely across populations, from 0.73% to 
14.4% in women and from 0.76% to 15.1% in men, but within each population was 
gender-related (47). 
This female excess in angina pectoris was found across countries with widely differing 
myocardial infarction mortality rates in women, was particularly high in the American 
studies, and was higher among nonwhite ethnic groups than among whites.
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Fig 4: Angina prevalence in 
women vs. men. Labels are 
given for populations in which 
the prevalence differs by at least 
2.5% between women and men.
Reproduced with permission of 
Circulation
Angina prevalence in woman vs men
Hemingway, H et al. Circulation 2008;117:1526-1536
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This remarkably consistent female angina excess across countries, spanning 4 decades 
of study and 4 decades of participant’s age is intriguing. Such generalizability suggests 
an inherent biological basis rather than artifactual explanations. Furthermore there is 
the paradox of the male preponderance of patients who reach coronary angiography. 
This suggests a female underuse of cardiac investigation; in the diagnostic work-up 
women are lost by cardiologists.
Women experience atypical chest pain more often than men, a result that is a challenge 
to the cardiologist. 
Furthermore, the mondial prevalence of CSX in unclear due to racial heterogeneity. 
As stated in the ‘Journal of Health Care for the Poor and the Underserved’, there is a 
higher prevalence of normal coronary angiograms in African Americans with angina 
compared to whites (48). Indo Asians on the other hand do have smaller coronary 
arteries compared to Caucasians, owing to the smaller body size (46). Studies in heart 
transplants and transsexual patients show that large arteries are inherently smaller 
in women, independent of body size, and such smaller coronary arteries may be 
associated with ischaemia.
In the Netherlands 298.100 angina pectoris patients were reported on 01-01-2007, 
consisting of 168200 men (20.8 per 1000) and 129.900 women (15.7 per 1000) (49). It 
is unknown how many patients had a positive ergometric result and how many of these 
had normal CAGs, i.e. how many might be categorized as CSX patients. Incidentally, 
international data on the incidence of CSX are also unavailable or unknown. 
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Outline of this thesis
Chapter 1. We present a case study of one of our first CSX patients. Introductory 
remarks on the subject are made and the current ideas on pathogenesis, diagnostic 
criteria, gender and prevalence are shortly discussed.
Chapter 2 is a systematic review on the definition of cardiac syndrome X.  The effects 
of using different inclusion and exclusion criteria on CSX incidence and prevalence are 
described. The criteria are also applied on the 567 patients who underwent a coronary 
angiography study in the Spaarne Hospital, Haarlem, in 2003.
Chapter 3. Endothelial dysfunction might play a role in the pathogenesis of 
microvascular angina and the endothelin-A receptor is probably involved in CSX patients 
with mental distress. Blocking this receptor has also shown to be effective in patients 
with coronary vasospasm, especially when other medication fails. In a patient with 
coronary vasospasm we studied the effects of bosentan on myocardial perfusion with 
PET, using 15O-labeled H2O.
Chapter 4. The presumed association between anxiety and the extent of myocardial 
ischaemia was studied in 20 CSX patients. 99mTc Myoview SPECT studies were scored by 
3 experienced readers, having no knowledge of the STAI (State-Trait Anxiety Inventory) 
screening results.
Chapter 5. In cardiac syndrome X, the ischaemic origin of reversible perfusion defects 
is still debated. There are also questions on the reproducibility, the size and the 
distribution of ischaemic defects in microvascular angina (6). We compared CMR (first-
pass perfusion) and standard SPECT in CSX patients.
Chapter 6. High resolution imaging with first-pass perfusion CMR suggested the 
presence of subendocardial hypoperfusion in CSX patients (12).This study asked for 
confirmation since a new and reliable non-invasive method for microvascular dysfunction 
was badly needed.
Chapter 7. Myocardial blood flow (MBF) measurements with the PET technique and the 
tracers 82Rb (Sr-Rb generator), 13N-labeled NH3 and 15O-labeled H2O (both cyclotron 
products) are the future in the nuclear cardiology. Sensitivity and specificity for ischemia 
are > 90 % and functional flow reserve can be assessed in quantitative terms. A further 
improvement might be that endocardial and epicardial perfusion can be measured 
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separately. The present study in healthy volunteers was designed to provide the normal 
values for these parameters.
 
Chapter 8.  Prognosis in CSX has generally been considered as excellent. A recent 
study, however, was less optimistic (50). Adverse outcomes, especially in women, had 
been found. Enough reason for an actual systematic review on incidence and prognosis 
in CSX, with particular attention for gender.
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2 Definitions and incidence of cardiac syndrome X: review and analysis of clinical data
ABSTRACT
There is no consensus regarding the definition of cardiac syndrome X (CSX). We 
systematic reviewed recent literature using a standardized search strategy. We included 
57 articles. A total of 47 studies mentioned a male/female distribution. A meta-analysis 
yielded a pooled proportion of females of 0.56 (n=1934 patients, with 95% confidence 
interval: 0.54-0.59). Nine different inclusion criteria and forty-three exclusion criteria 
were found in the 57 articles. Applying these inclusion- and exclusion criteria upon 
a population with normal coronary angiograms treated in one year at a general 
hospital, the attributable CSX incidence varied between 3% and 11%. The wide range 
of definitions has large affects on the incidence. This shows the need for a generally 
accepted definition of CSX.
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INTRODUCTION
The syndrome of angina pectoris with a normal coronary arteriogram, often termed 
cardiac syndrome X (CSX) is an important clinical entity. (1) About 20 % of patients with 
anginal chest pain have normal coronary angiograms (CAG). Some physicians regard 
this as sufficient to diagnose CSX, the so-called broad diagnosis of CSX. (1, 2) However, 
the cause of CSX is not conclusively established and its definition is controversial. For 
example, a subgroup of these patients has objective signs of ischaemia, such as the 
classic downsloping ST-segment depression on exercise testing and/or a reversible 
defect detected by myocardial single-photon emission computed tomography (SPECT). 
Consequently, other authorities consider that CSX is discounted by a positive result 
from any diagnostic test for ischaemia, especially SPECT; and there is also the view that 
CSX might best be relabelled as one of several causes of microvascular dysfunction. (3) 
Furthermore, there are various exclusion criteria, such as hypertension and diabetes, 
that may or may not be used to discount the diagnosis of CSX. Finally, in overviews 
and textbooks it is often stated that (pre menopausal) women are especially prone for 
developing cardiac syndrome X. Indeed, some authors exclusively study female patient 
populations but there is considerable variation in the proportion of women in other 
studies of CSX patients.
The present paper is a review to determine the gender and main definitions for CSX in 
the recent literature and also the effects of different definitions upon the attributable 
CSX incidence. To study this latter aspect we examined and analyzed the CAG data for 
a population of patients treated in a general hospital in the Netherlands.
METHODS
CSX definitions
The PubMed database was used to identify papers in which criteria and definitions 
for CSX are described. Our search consisted of ‘(cardiac syndrome x[tiab]) NOT (case 
reports[pt] OR comment[pt] OR review[pt])’, with limits set to English language, 
humans, and publication date between June 2003 and July 2008. We limited our 
search strategy to cardiac syndrome X and excluded metabolic syndrome X and tako-
tsubo cardiomyopathy. (4-6)
This search yielded 112 references. Conference abstracts, pediatric papers, and 
‘epublications ahead of print’ were excluded. Of 83 articles the full text was retrieved 
for further analysis. Articles were independently surveyed by 2 authors (IV and GT) and 
reviewed with regard their used definition of CSX. For this review remained 57 studies. 
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Impact of CSX definition upon CSX incidence
All the CAGs made in 2003 in a large general hospital in the Netherlands were collected. 
An extensive search was made to obtain the clinical history, physical examination, 
routine laboratory tests and echocardiography results for all patients with CAGs stated 
to be completely normal. All CAGs were independently evaluated by two experienced 
observers (AK, DO).
Only patients with original angiograms and sufficient clinical data were included in the 
present study.
TABLE 1: inclusion criteria for CSX
Inclusion criteria for CSX Number of studies
Angina pectoris 18
Positive exercise stress test
Normal coronary arteries
Effort induced angina pectoris 17
Positive exercise stress test
Normal coronary arteries
Angina pectoris 11
Positive exercise stress test OR positive SPECT
Normal coronary arteries
Angina pectoris 4
Normal coronary arteries
Angina pectoris 4
Positive exercise stress test AND positive SPECT
Normal coronary arteries
Angina pectoris 1
Positive exercise stress test
No significant CAD on CAG,
Effort induced AP 1
Positive exercise stress test
Normal coronary arteries AND prolonged coronary flow on CAG
Angina pectoris 1
Positive exercise stress test
Normal coronary arteries AND reduced LVEF on echo
Angina pectoris 1
Positive SPECT
Normal coronary arteries
CSX= cardiac syndrome X, AP=angina pectoris, CAG= coronary angiogram, SPECT=single photon 
emission tomography, LVEF= left ventricular ejection fraction
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RESULTS
SX definitions
The 57 papers selected for determining the main definitions of CSX covered a total of 
2375 patients. A normal coronary angiogram was used in the majority of the studies. 
However, in a few studies minimal coronary artery disease, like atheromatous plaque 
without critical obstructions, is included as “normal coronary angiogram”. (7-9) A few 
studies state in the exclusion criteria minimal coronary artery disease. (10) But in the 
majority of the studies there was no statement regarding minimal artery disease. Only 
a few studies specified the interpretation of the normal coronary angiograms, like 
revision of the CAG films, blinded observation or interpretation by more reviewers.
Table 1 lists the nine CSX definitions, and hence inclusion criteria, obtained from our 
review of the 57 studies. Table 1.
In more detail: 
l	 Out of 57 studies 42 required positive exercise electrocardiograms for the diagnosis 
of CSX. The general criterion, when given, for a positive exercise stress test result 
was uniform ST depression ≥ 1 mm. Only one study considered stress-induced 
angina without significant ST depression to be positive for ischaemia. (11) 
l	 As much as 11 studies regarded positive myocardial perfusion images to be good 
alternatives to a positive result from exercise testing. 
l	 As much as 18 studies considered effort-induced angina pectoris as an inclusion 
criterion
l	 Four studies defined CSX simply as angina pectoris and normal CAG, the so-called 
broad diagnosis of CSX. 
Table 2 lists no less than forty-three exclusion criteria for CSX. The most frequently 
used exclusion criteria are valvular heart disease, diabetes mellitus, left ventricular 
hypertrophy, hypertension and cardiomyopathy. Table 2
TABLE 2: Exclusion criteria included studies
Exclusion criteria used in the studies for present review N studies of 57 total
Valvular heart disease 33
Diabetes mellitus 32
Left ventricular hypertrophy 26
Hypertension 24
Cardiomyopathy (non specified) 23
Renal failure 22
History of myocardial infarction 15
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TABLE 2: Cont.
Exclusion criteria used in the studies for present review N studies of 57 total
LV dysfunction 14
Coronary spasm 13
Hepatic dysfunction 12
Arrhytmias 9
Inflammatory disease 9
Dyslipidaemia 8
Left bundle branch block 8
Cardiac disease (non specified) 7
Gastro Intestinal disorder 7
Systemic disease (non specified) 6
Smoking 6
Thyroid dysfunction 5
Obesitas 5
Non-cardiac chest pain 5
Condunction disorder (incl LBTB) 5 (13)
Hypertrophic CMP (total CMP) 5 (23)
Congestive CMP (total CMP) 5 (23)
Dilated CMP (CMP total) 4 (23)
Alcoholism 4
Metabolic syndrome 4
Dysphagia/  oesophagitis 3
Malignancy 3
LVEF<40% 2
Psychiatric ilness 2
Auto immune disease 2
Estrogen replacement therapy 2
PTCA/CABG in history 2
Ectasia on CAG 2
Bridging on CAG 2
Claudicatio intermittens 2
Heart failure ( non specfied) (total) 1 (17)
Myocarditis 1
Congenital heart disease 1
Aortic wall diseases 1
Anaemia 1
Thrombocytopenia 1
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In overviews and textbooks it is often stated that (pre menopausal) women are 
especially prone for developing cardiac syndrome X. 
In Table 3 data of the individual studies are presented. Table 3 
In 53 out of the total of 57 included studies the female/male distribution of the study 
population was mentioned. Six studies were focused upon female patients with CSX. 
These studies were excluded for the pooling of the proportion of women in the study 
populations. Ultimately 47 studies with a total of 1, 934 patients could be used for the 
meta-analysis. 
TABLE 3: included studies of CSX patients
Included study of CSX patients year n Female (%) Mean age (Y)
Lee [41] 2008 21 81 55
Timurkaynak [61] 2008 79 54 50
Cemin [11] 2008 11 100 59
Zorc-Pleskovic [66] 2008 31 100 55
Lanza [38] 2008 18 61 58
Altun [2] 2007 9 77 49
Cotrim [12] 2008 91 48 51
Asbury [5] 2008 64 100 58
Demir [18] 2008 17 41 57
Grabczewska [23] 2007 53 57 55
Li [44] 2007 36 100 NA
Okyay [48] 2007 32 66 53
Dabek [15] 2007 34 65 57
Yildiz [64] 2007 10 79 49
Kayikcioglu [33] 2007 30 60 46
Mao [45] 2007 51 78 21
Dabek [14] 2007 36 65 57
Vermeltfoort [63] 2007 20 75 55
Galiuto [21] 2007 17 53 55
Alroy [1] 2007 42 100 52
Huang [29] 2007 12 60 63
Guzik [28] 2007 43 65 44
Gur [26] 2007 23 70 49
Gur [27] 2007 23 NA NA
Sgueglia [59] 2007 30 73 61
Russell [55] 2007 24 89 54
Sen [56] 2007 203 58 53
Shmilovich [60] 2007 17 71 58
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The proportion of women in the 47 studies of CSX patients varied considerably ranging 
from 0.21 to 1.0, with a pooled estimate of 0.56 (95% confidence interval: 0.54-0.59), 
see also figure 1. Hence, there is a significantly higher proportion of woman compared 
to males in the group of patients with CSX. 
TABLE 3: Cont.
Included study of CSX patients year n Female (%) Mean age (Y)
de Vries [17] 2006 42 26 58
Nam [47] 2006 52 NA NA
Eskandarian [19] 2006 40 73 46
Cay [10] 2006 126 62 53
Jadhav [30] 2006 52 100 56
Czepczynski [13] 2006 68 63 45
Leu [43] 2006 92 21 64
Lanza [40] 2005 10 59 70
Cay [9] 2005 80 52 51
On [49] 2005 36 53 36
Guo [25] 2005 22 68 48
Masci [46] 2005 41 NA 53
Senen [57] 2005 21 48 56
Pasqui [51] 2005 30 60 54
Sestito [58] 2005 30 73 60
De Candia [16] 2005 21 57 55
Valeriani [62] 2005 16 50 60
Cavusoglu [8] 2005 31 45 52
Kolasinska-Kloch [36] 2004 42 52 46
Kolasilska-Kloch [35] 2004 25 36 49
Altun [3] 2004 8 75 46
Asbury [4] 2004 100 100 61
Fabian [20] 2004 40 40 55
Lanza [39] 2004 55 50 57
Qian [54] 2004 126 47 53
Osamichi [50] 2004 24 71 58
Gorgulu [22] 2003 18 44 51
Pizzi [53] 2004 NA NA 59
Kidawa [34] 2003 50 64 49
NA= not available
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FIGURE 1: plot of proportion of women of individual studies, including 95% confidence intervals 
first author & year: proportion (95% Cl)
Lee 2008 0.81 0.58 - 0.95
Demir 2008 0.41 0.18 - 0.67
Timurkaynak 2008 0.54 0.43 - 0.66
Cemin 2008 1.00 0.72 - 1.00
Lanza 2008 0.61 0.36 - 0.83
Altun 2008 0.78 0.40 - 0.97
Cotrim 2008 0.48 0.38 - 0.59
Grabczewska 2007 0.57 0.42 - 0.70
Okyay 2007 0.66 0.47 - 0.81
Dabek 2007 0.65 0.46 - 0.80
Yildiz 2007 0.80 0.44 - 0.97
Kayikcioglu 2007 0.60 0.41 - 0.77
Mao 2007 0.78 0.65 - 0.89
Dabek 2007 0.64 0.46 - 0.79
Vermeltfoort 2007 0.75 0.51 - 0.91
Galiuto 2007 0.53 0.28 - 0.77
Huang 2007 0.58 0.28 - 0.85
Guzik 2007 0.65 0.49 - 0.79
Guzik 2007 0.70 0.47 - 0.87
Sgueglia 2007 0.73 0.54 - 0.88
Russell 2007 0.88 0.68 - 0.97
Shmilovich 2006 0.71 0.44 - 0.90
Sen 2007 0.58 0.51 - 0.65
de Vries 2006 0.26 0.14 - 0.42
Eskandarian 2006 0.73 0.56 - 0.85
Cay 2006 0.62 0.53 - 0.70
Czepczynski 2006 0.63 0.51 - 0.75
Leu2006 0.21 0.13 - 0.30
Kolasilska - Kloch 2004 0.36 0.18 - 0.57
Kolasilska - Kloch 2004 0.52 0.36 - 0.68
Cay 2005 0.53 0.41 - 0.64
On 2005 0.53 0.35 - 0.70
Guo 2005 0.68 0.45 - 0.86
Senen 2005 0.48 0.26 - 0.70
Pasqui 2005 0.60 0.41 - 0.77
Sestito 2005 0.73 0.54 - 0.88
De Candia 2005 0.57 0.34 - 0.78
Valeriani 2005 0.50 0.25 - 0.75
Cavusoglu 2005 0.45 0.27 - 0.64
Altun 2004 0.75 0.35 - 0.97
Lanza 2005 0.60 0.26 - 0.88
Fabian 2004 0.40 0.25 - 0.57
Lanza 2004 0.50 0.36 - 0.64
Qian 2004 0.47 0.38 - 0.56
Osamichi 2004 0.71 0.49 - 0.87
Gorgulu 2003 0.44 0.22 - 0.69
Kidawa 2003 0.64 0.49 - 0.77
pooled proportion : 0.56 (0.54 to 0.59)
0 0.2 0.4 0.6 0.8 1
proportion female patients
proportion female patients
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FIGURE 2: flowchart
CSX incidence
567 CAGs were performed in one year at a general hospital. Figure 2 is a flowchart 
showing how we analyzed the available information. 
indication for CAG:
valvular heart disease n=2
arrhytmia n=3
cardiomyopathy n=3
indication for CAG:
troponin release n=5
no angina pectoris n=7
left ventricular hypertrophy n=2
bridging n=1
patients with normal CAG
angina pectoris
no troponin release
n=60
patients with normal CAG
n=78
patients underwent CAG
year 2003
n=567
Patients underwent CAG
clinical data present
n=559
number of lost clinical data
n=8
Patients with abnormal CAG
n=481
no exercise test or
myocardial perfusion imaging
performed
n=15
exercise test and/or
myocardal perfusion imaging
performed
n=45
positive exercise test or
ischaemia on SPECT
n=28
history of myocardial infarction=1
coronary spasm n=2
diabetes mellitus n=2
cardiac syndrome X
Vumc criteria
n=18
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The main stages are:
l	 Original CAGs or clinical data could not be found for 8 patients, leaving 559 cases 
for analysis.
l	 78 (14%) of the available 559 CAGs were considered as absolutely normal.
l	 Excluding 13 cases with no angina pectoris as indication for CAG, and another 
5 with an acute coronary syndrome, resulted in an incidence of 60 (11%) CSX 
patients according to the broad diagnosis of CSX (angina pectoris and normal 
coronary arteries). (1, 2, 19, 35, 59)
l	 Another 15 cases were excluded owing to the lack of exercise stress tests or 
myocardial perfusion imaging preceding the CAG.
l	 Of the remaining 45 cases, 28 were included owing to positive results for ischaemia 
from exercise tests or SPECT.
l	 Finally, a much stricter definition of CSX was obtained by using the main exclusion 
criteria shown in the second-to-last stage in figure 2. This strict definition resulted in 
an attributable CSX incidence of 18 (3%) patients. 
DISCUSSION
CSX definitions and incidences
The present review of recent archival literature demonstrates that there is a wide range 
of definitions of CSX. This wide range of definitions has large effects on the attributable 
incidence of CSX, as has been shown by an analysis of all available CAGs and other 
clinical data for a population of patients treated in one year at a general hospital.
Generally it is stated that patients with chest pain and normal coronary arteriogram 
may represent as many as 10 to 20 % of those undergoing coronary arteriography 
because of clinical suspicion of angina. (1) This is in broad agreement with our analysis 
result that 11% of patients had a normal CAG. The rather low incidence of normal 
CAG can be the result of the use of rather strict criteria for a normal CAG including a 
consensus reading by two independent readers of the CAG’s.
It is generally accepted (e.g. in important textbooks) that the majority of the CSX 
patients are women. (1, 63) Some authors have suggested that CSX is a women’s 
disease, however, we found in this review of a pooled relative female frequency of 
56% in a population of more than 1900 CSX patients. Hence, our data do not support 
the assumption that CSX is a women’s disease since 44% is of male gender. Potential 
pathofysiological explanations, such as estrogen depletion, which are based upon the 
female gender apply only for a part of the CSX patients. (64) 
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Inclusion and exclusion criteria
The literature survey showed that the inclusion and exclusion criteria varied. This was 
especially the case for the exclusion criteria. 
The definition of ‘normal coronary arteries’ was particularly unclear. Most studies did 
not define a normal CAG, and some included patients with coronary artery disease 
(CAD) ranging from minimal to stenoses up to 50% of luminal diameter. Obviously, 
normal coronary arteries are the cornerstone of the diagnosis of CSX. Hence, there 
should be no doubt regarding the use of this inclusion criterion for studies of CSX 
patients. Future studies of CSX patients should make a clear description regarding the 
evaluation and results of the CAG studies of the coronary artery anatomy. 
The so-called broad diagnosis for CSX, a combination of 2 inclusion criteria (angina 
pectoris and normal coronary arteries) was used in only 4 studies (7%). 
Most studies used a combination of 3 inclusion criteria, namely (effort induced) angina 
pectoris, positive exercise test result and a normal CAG, as an inclusion criterion. This 
definition was used in 46 of 57 studies (81%). The use of this additional inclusion 
criterion resulted in a decrease of the incidence of CSX to 7 % in our population. 
The definition of a positive exercise stress test appears to be more standardized than 
the definition of a normal CAG. Most publications used a ST depression ≥1 mm as a 
positive exercise stress test, in only 12 of the 57 studies the definition of a positive 
stress test was not specified. 
The use of specific exclusion criteria ranged from 2 to 58% of the selected studies of 
CSX patients, often depending on the main objectives of the studies, for example the 
use of thrombocytopenia as an exclusion criterion in a study investigating the mean 
platelet volume. (43)
The most frequently mentioned exclusion criteria are valvular heart disease, diabetes mellitus, 
left ventricular hypertrophy, hypertension and cardiomyopathy. Microvascular dysfunction 
has been assessed in patients with diabetes mellitus and hypertension with normal CAG. 
Interestingly coronary flow reserve may be reversible in patients after anti-hypertensive 
therapy for instance. (65) However, regarding CSX definition in most international studies 
diabetes mellitus and hypertension are considered as exclusion criteria.
The existence of such a long list of exclusion criteria in the selection process of CSX 
patients illustrates the lack of agreement between the different research groups 
regarding the origins of this syndrome. Beside the use of a standard and fixed 
combination of inclusion criteria future studies should apply a standard combination 
of exclusion criteria. 
In a recent editorial Camici proposed following exclusion criteria in order to obtain a 
more homogeneous set of cardiac syndrome X patients: absence of left bundle branch 
block; absence of even minimal irregularities on the angiogram; no evidence of diabetes 
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mellitus, arterial hypertension, hyperlipidaemia, valve disease, epicardial arterial spasm, 
and cardiomyopathy. (66)
In our selection of CSX patients we decided to include only patients with completely 
normal coronary angiograms, effort-induced angina pectoris, positive exercise stress 
test and/or positive SPECT study. Furthermore, we decided to add arrhythmias, left 
ventricular hypertrophy, myocardial infarction in the medical history and myocardial 
bridging to the exclusion criteria proposed by Camici. These inclusion and exclusion 
criteria resulted in an attributable CSX incidence of only 3 %. 
CONCLUSION
The wide range of definitions of CSX in recent literature and the variations in inclusion and 
exclusion criteria, particularly the latter, make interpretation of the results of individual 
studies difficult. This shows the need for a generally accepted definition of CSX.
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Improved myocardial perfusion 
preceding clinical response on 
bosentan treatment for coronary 
vasospasm
Case report
SUMMARY
Many patients suffer from persistent angina due to coronary vasospasm despite optimal 
medical treatment. 
We treated a 46-year-old patient with severe and treatment resistant coronary 
vasospasm with the endothelin-receptor antagonist bosentan. Using oxygen-15-labeled 
water in conjunction with oxygen 15-labeled carbon monoxide Positron Emission 
Tomography, we measured an impaired coronary flow reserve (CFR) in 6 out of 13 
segments directly before the start of bosentan therapy. A repeated PET measurement 
after 16 weeks of bosentan treatment revealed a completely normalized CFR in this 
patient. Furthermore, the patient reported less frequent and less severe chest pain. 
Our data suggest a potential role of endothelin-receptor antagonists for patients with 
severe coronary vasospasms.
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In 2001 a 46-year old man suffered from a myocardial infarction caused by a significant 
stenosis of the left coronary artery, for which a bare metal stent was placed, and the 
patient was further treated with aspirin, a beta blocker, an ACE-inhibitor, and statins. 
His medical history further mentioned hypertension and hypercholesterolemia. Owing 
to persistent angina, in 2003 a coronary angiography was performed that showed 
no significant stenoses of the coronary arteries. Provocation with intracoronary 
acetylcholine-injection induced severe multivessel proximal and distal coronary 
vasospasm and chest pain. A diagnosis of coronary vasospasm was made and the patient 
was additionally treated with long-acting calcium antagonists and nitrate. Despite this 
medication, daily severe complaints of angina persisted. Since treatment with calcium 
antagonist and nitrate was at maximal dosage and daily severe chest pain persisted, 
we started additional treatment with bosentan (Tracleer®, Actelion Pharmaceuticals, 
Switzerland) according to the protocol used in patients with pulmonary hypertension. 
An oral dose of 62,5 mg b.i.d. was given for one month, followed by three months of 
125 mg b.i.d. After six weeks, complaints significantly decreased: chest pain was clearly 
less severe and the attacks occurred less often. Side effects of bosentan consisted of 
nasopharyngitis, hypotension, and flushing.  
A PET study using the tracer  H2
15O in conjunction of  C15O showed before the start of 
bosentan therapy an abnormal coronary flow reserve (CFR<2.0) in 6 out of 13 segments 
explaining the patient’s severe chest pain. The mean rest myocardial blood flow value 
was 0.9 ± 0.3 mL/min/mL myocardial tissue. The mean stress myocardial blood flow 
value was 1.8 ± 1.2 mL/min/mL myocardial tissue (see figure 1). The mean coronary 
flow reserve was 2.0 ± 1.4.
After 16 weeks of bosentan therapy the study was repeated. The coronary flow reserve 
quantitatively measured by PET was totally normal in all segments. The mean rest 
myocardial blood flow value was 1.3 ± 0.4 mL/min/mL myocardial tissue. The mean 
stress myocardial blood flow value was 6.5 ± 3.0 mL/min/mL myocardial tissue (see 
figure 1). The mean coronary flow reserve after bosentan therapy was 4.9 ± 3.5. 
This case report is the first to show a beneficial effect of treatment with the endothelin-
receptor antagonist bosentan in a patient with severe, treatment-resistant, vasospastic 
angina. After 16 weeks of bosentan therapy the clinical complaints of angina greatly 
decreased and the coronary flow reserve was completely normalized. 
In 1959 Prinzmetal and colleagues described an unusual syndrome of cardiac pain 
secondary to myocardial ischaemia. This pain occurred almost exclusively at rest and 
was associated with ST segment elevations on the ECG. The original hypothesis of 
Prinzmetal and colleagues, that variant angina is the result of transient increases in 
coronary vasomotor tone or vasospasm, has been convincingly demonstrated by coronary 
angiography. The coronary spasm can be induced by intracoronary acetylcholine (Ach), 
which causes vasodilatation when the endothelium is functioning normally. The spasm 
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is promptly relieved by nitroglycerin, which causes vasodilation through its direct action 
on the smooth muscle. This phenomenon suggests the possibility that patients with 
coronary spasm have a disturbance in the endothelial function of their coronary arteries 
(1-3). Endothelial dysfunction appears to be mediated by endothelin (2,4-6). Endothelin 
has two known receptor subtypes, ETA and ETB. ETA is located predominately on 
vascular smooth muscle cells (VSMC) and induces a vasoconstrictor effect, while ETB is 
located on endothelial cells and VSMC, and has both a vasoconstrictor and vasodilator 
effect. 
Bosentan is the first endothelin-receptor antagonist with an affinity for both ETA 
and ETB. Bosentan is an effective treatment for primary pulmonary hypertension (7). 
Recently, Allanore et al. reported the increase of myocardial perfusion using magnetic 
resonance imaging after bosentan treatment in patients with systemic sclerosis, a 
disease associated with an abnormal vasoreactivity in the microcirculation (8).
FIGURE 1: Short-axis images indicating absolute myocardial blood before bosentan at rest (A) 
and during stress (B). Panel C and D show myocardial blood flow after bosentan at rest (C) and 
during stress (D)
44
Medical treatment for vasospastic angina includes (besides risk factor modification) 
a calcium antagonist on its own or in combination with long acting nitrates. Other 
therapeutic options like prazosin, a selective alpha adrenoreceptor blocker, oestradiol 
supplementation and endoscopic thoracic symphatectomy have also been reported to 
be of value (9-11). 
As we have shown, endothelin receptor antagonists like bosentan may be effective in 
patients with severe coronary spasms, especially when other treatment fails. However, 
more studies are needed to assess the exact therapeutic value of these agents.Although 
this is a preliminary observation, our data suggest a potential role of bosentan for 
patients with severe therapy-resistant coronary vasospasms.
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Association between anxiety 
disorder and the extent of ischemia 
observed in cardiac syndrome X
ABSTRACT 
Background: A possible link between the heart and brain has been reported for cardiac 
syndrome X. Anxiety disorder could be a pathophysiological mechanism for this cardiac 
chest pain. To the authors’ knowledge, a quantitative analysis correlating anxiety with 
the extent of ischemia has not been done.
Methods and Results: In this pilot study we evaluated 20 patients with typical chest 
pain and completely normal coronary angiograms. These patients were screened with 
the State Scale (SS) and Trait Scale (TS) of the State-Trait Anxiety Inventory (STAI). All 
patients underwent myocardial perfusion scintigraphic imaging. The scintigrams were 
scored by 3 experienced readers having no knowledge of the STAI screening results. 
Patients with a low trait anxiety had significantly less ischemic segments on the 
myocardial perfusion imaging than patients with a high trait anxiety (1.8 ± 1.9 vs. 3.5 ± 
0.6, p<0.05). For state anxiety no significant differences could be found.
Conclusion: Cardiac syndrome X patients with high trait anxiety are at risk of having 
more ischemia.
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INTRODUCTION
About 20 % of patients with anginal chest pain have normal coronary angiograms. (1, 
2) The term “cardiac syndrome X “ (CSX) was introduced to describe these patients. 
(3, 4) A subgroup of these patients has objective signs of ischemia, such as the classic 
downsloping ST-segment depression on exercise testing and/or a reversible defect 
detected by myocardial single-photon emission computed tomography (SPECT). (5-9)  
The pathogenesis of cardiac syndrome X (CSX) remains uncertain. Two mechanisms 
have been proposed: ischemia caused by coronary microvascular dysfunction, and 
enhanced cardiac pain sensitivity (“sensitive heart” syndrome). (10)
Several studies found abnormalities consistent with ischemia in patients with syndrome 
X using scintigraphic myocardial perfusion imaging(5-9), thermodilution (11), nuclear 
magnetic resonance spectroscopy (12), intracoronary acetylcholine(13, 14), atrial 
pacing(15) and cardiac magnetic resonance (CMR) imaging. (16, 17)  These CMR 
studies support the hypothesis of microvascular ischemia in CSX patients. There are also 
PET studies demonstrating a reduced coronary flow reserve in CSX patients. (18-20) On 
the other hand, a recent CMR study found no impairment of subendocardial blood flow 
response in CSX patients,(21) and a PET study by Rosen et al showed no differences in 
myocardial blood flow between CSX patients and healthy controls. (22) 
In the last few years, attention has been paid to the effect of psychological factors 
on coronary artery disease (e.g. atherosclerosis) and cardiac neural mechanisms. (23) 
Previous work identified the importance of impaired myocardial blood flow, particularly 
in the microvascular bed, in relation to mental stress,(24, 25) and the phenomenon 
of endothelial dysfunction induced by mental stress has been described in CSX. (26) 
Furthermore, CSX patients have significantly higher levels of anxiety. (27) 
Owing to the conflicting data regarding ischemia in CSX patients, and also the possible 
role of anxiety, we performed a pilot study to measure the extent of ischemia and 
anxiety levels in a group of CSX patients.
METHODS
Patients
The pilot study population consisted of 20 patients from the outpatient clinic of the 
cardiology department in a general hospital (February 2004-September 2004). All 
patients exhibited typical chest pain, positive exercise stress testing (0.1 mV horizontal 
or downsloping ST-segment depression of 80 msec after the J point) and/or a 
reversible perfusion defect on a myocardial single photon emission tomograph (SPECT). 
Furthermore, all patients had completely normal coronary angiograms (CAG’s). This 
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was independently confirmed by two cardiologists in separate viewing sessions and 
without clinical information. 
The patients’ characteristics are given in table 1. None of the patients had a 
percutaneous transluminal coronary angioplasty (PTCA); coronary artery bypass 
grafting (CABG) or prior myocardial infarction; coronary spasm during the coronary 
angiography; absence of pain without medication; pregnancy; hypertension (defined 
as blood pressure over 140/90 mm Hg); diabetes (defined by a fasting glucose level 
above 7.8 mmol per litre or a random-sample glucose level above 11.1 mmol per litre); 
arrhythmias such as paroxysmal atrial fibrillation (PAF); left bundle branch block; valve 
dysfunction (other than mitral valve insufficiency  grade 1);  abnormal left ventricle 
ejection fraction ( LVEF<50 %) or other structural abnormalities of the heart. Also, 
none of the patients had electrographic signs of left ventricular hypertrophy  (defined 
as a value above 35 mm for the sum of the height of the S wave in lead V1 and the 
height of the R wave in lead V5)(28), or any
 change in clinical condition between the 
investigations. 
The study complied with the Declaration of Helsinki, the institutional ethics committee 
approved this study, and all patients gave written informed consent.
TABLE 1: patients’ characteristics
Patient’s characteristics Value
Age, mean ± SD (years) 55 ± 11
Women, n (%) 14 (70%)
Smoker, n (%)  3 (15%)
Hypertension 0 (0%)
CAD in family 13 (65%)
Hyperventilation 1 (5%)
Time between onset angina and first visit cardiologist, mean ± SD (years) 3.1 ± 8.1
Number of coronary angiograms, mean ± SD 1.2 ± 0.5
Number of patients using cardiac drugs 8 (40%)
Number of patients restricted in daily living due to angina pectoris 6 (30%)
Number of patients restricted in sport due to chest pain 5 (25%)
Number of patients experiencing chest pain during emotional stress 7 (35%)
Screening for anxiety
Patients were recruited for a questionnaire study after their visit to the outpatient clinic 
of the cardiology department. State anxiety was measured by the State Scale (SS) and 
trait anxiety by the Trait Scale (TS) of the State-Trait Anxiety Inventory (STAI Dutch 
version revised by van der Ploeg, Defares and Spielberger). (29, 30) This self-report 
scale measures the current symptoms of anxiety (state scale) and the participants’ 
predisposition to anxiety (trait scale). It consists of 2x20 self-report items, and earlier 
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use has shown good internal consistency (a = 0.87 – 0.92) and validity. For analysis, 
the subjects were categorized as having low (score<40) or high (score >40) state and 
trait anxiety. (31, 32)
For all the patients the questionnaires were supplemented by reviews of medical records 
and by a general questionnaire, including indices of socio-economic status (education, 
marital status, and current employment).
Myocardial perfusion SPECT (stress-rest 2 days protocol)
The first day was allocated to the stress (exercise) study. Patients were instructed to 
stop all cardiac medication 24 hours before testing, and to have a light breakfast. They 
had not consumed caffeine-containing beverages for 24 hours before the test. An 
intravenous line of normal saline solution, with a 20-gauge cannula, was positioned 
in an antecubal vein. The exercise was performed on a calibrated ergometer using a 
symptom-limited test with stepwise increased work. A 12-lead electrocardiogram and 
blood pressure were monitored throughout the study. SPECT imaging was performed 
45-60 minutes after peak exercise radiotracer injection. 
On day two the patients underwent an at-rest study. Acquisition parameters were 
identical to those for the stress study. 
SPECT imaging was performed on a double-headed gamma camera with a high-
resolution collimator. A symmetric 20 % window was centred at 140 KeV, with a 
three-lead electric cardiographic monitoring. Imaging was acquired into a 64x64 
computer matrix through a 180° rotation, with 32 positions; starting position is 
RAO 45°, with 8 frames per cycle. Bull’s-eye generation, and visual analysis using a 
19-segmental model were performed. 
Three experienced observers interpreted the SPECT results. Perfusion was graded on 
a scale of 0 to 4, with 0 representing normal perfusion and 4 representing a very 
severe perfusion defect. Perfusion defects graded one or more points below the at-rest 
SPECT results were considered to be ischemic. Consensus was obtained in cases of 
disagreement. Also, the observers had not been informed of the STAI results. 
Statistical analysis 
Variables like the STAI trait and state score, and the number of reversible segments in 
the SPECT study were expressed as mean ± standard deviation (SD). The numbers of 
patients (n) are expressed as absolute values and percentages of total (%). Variables 
were contrasted between 2 groups of low or high anxiety using an unpaired student 
test (two-sided), for both the state and the trait STAI groups. A p value less than 0.05 
was considered to be significant. 
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RESULTS
Table 2 lists the state anxiety and trait anxiety scores and the locations of ischemia on 
SPECT for all the patients. 
State STAI
Six (6) patients had high state anxiety levels. These patients had a mean of 3.0 ± 1.6 
reversible perfusion defects on SPECT. This value was not significantly different from 
the mean of 2.0 ± 2.0 reversible perfusion defects for patients with low state anxiety 
levels.
TABLE 2: anxiety scores and location of ischaemia for individual patients
patients
State 
anxiety
Trait 
anxiety
Number of ischaemic 
segments Location of ischaemia
1 53 52 3 Anterior (m), apical
2 34 36 1 Anterior (b)
3 20 20 4 Posterolat(b), inferoseptal(b+m), inferior(m)
4 27 24 0
5 41 40 0
6 51 56 4 Anterior (d), posterolat (b+m+d)
7 22 23 5 Anterolat (b+m), anteroseptal (b+m+d)
8 31 44 3 Inferior (b), anterolat (b), apical
9 52 58 3 Inferior (b+m), posterolat (b+m)
10 39 36 5 Inferior (b+m), posterolat (b+m)
11 24 26 0
12 33 36 0
13 39 34 2 Inferior (b), posterolat (b)
14 36 29 1 Anteroseptal (b)
15 41 44 4 Anterior (b+m+d), anteroseptal (d)
16 38 38 4 Anterior (b+m), apical, anterolat (d)
17 25 22 1 Inferior (b)
18 51 56 4 Posterolat (b), inferior (b+m), apical
19 24 24 0
20 36 39 2 Anteroseptal (m+d)
State anxiety is considered increased with scores >40
Trait anxiety is considered increased with scores >40
B=basal, m=mid, d=distal segment
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Trait STAI
Six (6) patients had a high trait anxiety score, reflecting a high predisposition to anxiety. 
These patients had a mean of 3.5 ± 0.6 reversible perfusion defects on SPECT. This value 
was significantly different (p < 0.05) from the mean of 1.8 ± 1.9 reversible perfusion 
defects for patients with low trait anxiety scores. Figure 1 illustrates this difference.
FIGURE 1: Patients with a high 
trait anxiety had significant more 
ischaemic segments on SPECT. 
Mean values ± SD
TABLE 3: characteristics of patients with high versus low trait anxiety
Patient’s characteristics
 High Trait anxiety
(n=6)
Low trait anxiety
(n=14)
P 
value
Age, mean ± SD (years) 55 ± 15 55 ± 9 NS
Woman, % 67 65 NS
Smoker, % 17 14 NS
CAD in family, % 33 78 NS
Time between onset angina and first visit 
cardiologist, mean ±SD (years)
 2.2 ± 3.9 3.2 ± 9.1 NS
Cardiac drugs, % 33 43 NS
Restricted in daily living due to angina pectoris, % 50 21 NS
Restricted in sport due to chest pain, % 33 21 NS
Chest pain during emotional stress, % 67 21 NS
low trait anxiety high trait anxiety 
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Cross-sectional comparisons between those with high or low trait anxiety 
scores
Table 3 compares the patients with high and low scores for trait anxiety on the basis 
of demographic and medical variables. There is a trend for high trait anxiety patients 
to have more frequent chest pain during emotional stress, and they were also more 
frequently restricted in daily living as well as in practicing sports. However, none of the 
differences were statistically significant.
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DISCUSSION
This study demonstrates the association between high trait anxiety and the extent of 
ischemia in cardiac syndrome X patients. This suggests that trait anxiety is associated 
with an increased risk of exercise-induced ischemia and that high trait anxiety might 
be a predisposing risk factor for cardiovascular damage causing reversible perfusion 
defects on the SPECT imaging of CSX patients.
As mentioned in the introduction to this paper, attention has recently been paid 
to the effect of psychological factors on coronary artery disease and cardiac neural 
mechanisms. (23) Previous work identified the importance of impaired myocardial 
blood flow, particularly in the microvascular bed, in relation to ischemia induced by 
mental stress,(24, 25) and the phenomenon of endothelial dysfunction induced by 
mental stress has been described in CSX. (26)
Sudden emotional stress can lead to myocardial stunning in healthy subjects 
without CAD, probably owing to exaggerated sympathetic stimulation that causes 
vasoconstriction. (33) Similarly, increased sympathetic tone from mental stress can 
cause vasoconstriction in patients without coronary disease, such as in CSX. (33, 34) 
The association between endothelial dysfunction and mental stress in CSX is reported 
in a SPECT study by Peix et al. (26) CSX patients were asked to focus on an incident in 
their lives that made them very angry, and SPECT imaging was done during this period 
of mental stress. A total of 6 out of 16 patients had SPECT-imaged reversible perfusion 
defects, and this correlated with more frequent endothelial dysfunction measured by 
brachial artery flow-mediated dilation. 
A limitation of the study by Peix et al(26) is the non-standard mental stress test, since it 
cannot be assumed that the subjects were exposed to  similar levels of mental stress. We 
have attempted in our pilot study to avoid this limitation by using validated standardized 
questionnaires for anxiety disorders to measure the anxiety predispositions and levels 
of each CSX patient. As mentioned earlier, state anxiety was measured by the State 
Scale (SS) and trait anxiety by the Trait Scale (TS) of the State-Trait Anxiety Inventory 
(STAI Dutch version revised by van der Ploeg, Defares and Spielberger). (29, 30)
Interestingly, a recent study of CAD patients showed that mental stress provokes a 
different myocardial ischemic response compared to exercise or adenosine. (35)
However, there a little data available for patients groups with normal coronary arteries 
or syndrome X.
There are limited previous data on anxiety disorder and its relation to endothelial 
dysfunction. Narita et al. (36) used brachial artery flow measurements to investigate 
anxiety levels and endothelial dysfunction in elderly males. They found no link between 
high state anxiety levels and endothelial dysfunction, but there was a link for high trait 
anxiety. This result is broadly similar to that of our study, in which we showed that CSX 
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patients with high trait anxiety are at risk of having more extended ischemia compared 
to CSX patients with low trait anxiety.
Reasons for differences in the state and trait anxiety results
(1) In our study, the lack of significance in the extent of ischemia between CSX 
patients with high and low state anxiety levels could have two reasons: firstly the 
small population of 20 patients, and secondly the time delay between state anxiety 
measurements and SPECT scanning. This latter possibility is because state anxiety 
levels may differ at different times. Obviously, a more definitive study involving a 
larger population is needed, whereby myocardial ischemia is investigated for state 
and trait anxiety levels at one time.
(2) A pathophysiological explanation for the different findings between the state and 
trait anxiety levels may be the different effects they have on the development 
of ischemia. State anxiety reflects a transitory emotional condition characterized 
by subjective feelings of tension, and is associated with heightened autonomic 
nervous system activity. Trait anxiety, on the other hand, reflects the existence of 
a certain predisposition to anxiety. A high predisposition to anxiety could reflect 
a chronic stress condition with long-term high anxiety levels. In turn, high anxiety 
levels are most probably a risk factor for cardiovascular damage only when they 
are sustained for long periods.
This hypothesis may also help to explain the results of Narita et al. (36), in particular 
their result that there was a significant association between trait anxiety and endothelial 
dysfunction for elderly males but not for young ones. 
CONCLUSIONS
This pilot study showed that CSX patients with high trait anxiety are at risk of having 
more extended ischemia compared to CSX patients with low trait anxiety. This suggests 
that anxiety-induced ischemia can occur in CSX patients, and that high trait anxiety 
might be a predisposing risk factor for cardiovascular damage causing reversible 
perfusion defects on the SPECT imaging of CSX patients
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Is subendocardial ischemia present 
in patients with chest pain and 
normal coronary angiograms? 
A cardiovascular MR study
ABSTRACT
Aims: Based upon a MRI study it has been suggested that subendocardial hypoperfusion 
is present in patients with cardiac syndrome X. However, further work is required to 
test whether these findings can be generalized.
Methods and results: MRI was used to visually and semi-quantitatively assess 
subendocardial and subepicardial perfusion, at rest and during an infusion of adenosine, 
in 20 patients with angina pectoris and normal coronary angiograms. A myocardial 
perfusion index (MPI) was calculated using the normalized upslope of myocardial signal 
enhancement. An index for myocardial perfusion reserve (MPRI) was calculated by 
dividing the MPI values at maximal vasodilatation by the values at rest.
The myocardial perfusion index (MPI) in our study population increased significantly 
during adenosine infusion in both the subendocardium (from 0.091 ± 0.020 to 0.143 ± 
0.030: p<0.001) and the subepicardium (from 0.074 ± 0.017 to 0.135 ± 0.03: p<0.001). 
The overall MPRI was 1.83 ± 0.50.
Conclusion: The results show that patients with chest pain and normal coronary 
angiograms had significant perfusion responses to adenosine in both the subendocardium 
and subepicardium. In the present study we found no evidence for subendocardial 
hypoperfusion in these patients.
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INTRODUCTION
About 20 % of patients with anginal chest pain have normal coronary angiograms 
(1-5). The term “cardiac syndrome X” was introduced to describe these patients (6, 7). 
However, a subgroup of these patients has objective signs of ischaemia, such as the 
classic downsloping ST-segment depression on exercise testing and/or a reversible defect 
detected by myocardial single-photon emission computed tomography (SPECT)(8-13).
The pathogenesis of syndrome X is unclear. Physiological mechanisms have been 
proposed, such as the existence of myocardial ischemia that might be caused by 
coronary microvascular dysfunction or an abnormal pain perception (14). Several 
studies found abnormalities consistent with ischemia in patients with syndrome X 
using positron emission tomography (PET)(1), scintigraphic myocardial perfusion 
imaging (8, 11, 13), thermodilution (15), nuclear magnetic resonance spectroscopy 
(16), intracoronary acetylcholine (17, 18) and atrial pacing (19). However other 
investigators have questioned the proposed role of coronary microvascular dysfunction 
in syndrome X, Rosen et al found no differences in myocardial blood flow between 
syndrome X patients and healthy controls (20). Furthermore, in studies using stress 
echocardiography and myocardial metabolic measurements no evidence of ischemia 
was found in patients with syndrome X (4, 5, 20-24).
High resolution imaging with MRI offers the possibility to study subendocardial and 
subepicardial myocardial blood flow (25, 26). An interesting MRI study suggested 
the presence of subendocardial hypoperfusion in patients with syndrome X (27). The 
authors suggested that further work is required to test whether these findings can 
be generalized. To our knowledge the results of this study have not been confirmed. 
Therefore we employed MRI to visually and semi-quantitatively assess subendocardial 
and subepicardial perfusion, at rest and under stress during adenosine infusion in 20 
patients with angina pectoris, objective signs of ischemia (ST segment depression during 
exercise test and/ or reversible defect on SPECT) and normal coronary angiograms.
METHODS
Patient characteristics and inclusion/exclusion criteria
We identified 34 patients with typical chest pain and normal coronary angiograms: 
22 women and 12 men. All had established (1999 – 2004) exertional angina; an 
abnormal exercise electrocardiogram suggesting ischemia (0.1 mV horizontal or 
downsloping ST-segment depression of 80 msec after the J point) and/or a reversible 
perfusion defect on a myocardial SPECT; and completely normal results from coronary 
angiography, which was independently confirmed by two cardiologists in separate 
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viewing sessions and without clinical information. The mean time between coronary 
angiography and CMR was 11.6 months. Furthermore, the time between myocardial 
perfusion scintigraphy and coronary angiography was 2.5 months, the time between 
SPECT and CMR was 12.4 months.
The exclusion criteria were: a percutaneous transluminal coronary angioplasty (PTCA); 
coronary artery bypass grafting (CABG) or prior myocardial infarction; coronary spasm 
during the coronary angiography; absence of pain without medication; pregnancy; 
hypertension (defined as blood pressure over 140/90 mm Hg); diabetes (defined by 
a fasting glucose level above 7.8 mmol per litre or a random-sample glucose level 
above 11.1 mmol per litre); arrhythmias such as paroxysmal atrial fibrillation (PAF); left 
bundle branch block; valve dysfunction (other than mitral valve insufficiency grade 1); 
abnormal left ventricle ejection fraction ( LVEF<50 %) or other structural abnormalities 
of the heart. Furthermore, patients having general contra-indications for MRI according 
to the MR safe practice guidelines were also excluded (28). None of the patients had 
electrographic signs of left ventricular hypertrophy (defined as a value above 35 mm for 
the sum of the height of the S wave in lead V1 and the height of the R wave in lead V5)
(29), or any change in clinical condition between the investigations. 
Finally 20 of the 34 identified patients were selected for first pass contrast cardiovascular 
MR. These patients’ characteristics are given in table 1. The reasons for excluding the 
other 14 patients from the MRI study were: absence of pain without medication (n=2); 
claustrophobia (n=8); 1 patient did not fit into the MRI scanner owing to obesity (height 
167 cm, weight 120 kg); 1 patient cancelled due to negative advice from his physician; 
1 patient had moved to an unknown address; and 1 patient’s original coronary 
angiogram data were unavailable for the independent evaluation by two cardiologists.
In addition to the characteristics in table 1, the selected patients were examined in more 
detail as follows, the SPECT results showed reversible perfusion defects in 16 patients, 
1 patient had a reversed perfusion pattern, 1 patient showed normal perfusion, and 
a mild fixed defect was seen in 2 patients. An abnormal exercise electrocardiogram 
Table 1: Patients’ characteristics
Characteristic Value
Age, mean ± SD (years) 55 ± 11
Women, n (%) 15 (75%)
Smoker, n (%)   5 (28%)
Cholesterol, mean ± SD (mmol per litre) 5.7 ± 1.7
Glucose, mean ± SD (mmol/litre) 5.1 ± 0.64
Blood pressure systolic, mean (mm Hg) 129 ± 15
Blood pressure diastolic, mean (mm Hg) 73 ± 8
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suggesting ischaemia (0.1 mV horizontal or downsloping ST-segment depression of 
80 msec after the J point) was present in 5 patients, 8 patients developed chest pain 
without significant ST-segment depression. The patients received hormonal replacement 
therapy (1 patient), calcium-channel blockers (7 patients), nitrates (4 patients), beta-
blockers (6 patients), ACE inhibitors (1 patient), or no treatment (5 patients). These 
numbers reflect the fact that some patients received a combination of these drugs.
The study complies with the Declaration of Helsinki, institutional ethics committee 
approved this study, and all patients gave written informed consent.
MRI scan protocol 
The patients were instructed to stop all cardiac medication and refrain from caffeine-
containing beverages 24 hours before cardiovascular MRI, and to eat light breakfast 
on the day of the test. Patients receiving beta-blocking drugs stopped their medication 
for at least three half life times. Before testing, an intravenous line of normal saline 
solution, with a 20-gauge canula was positioned in the antecubal veins in both arms. 
We used a single cannula for administration of contrast and a separate cannula for the 
administration of adenosine.
Imaging was performed with a 1.5T whole body MRI scanner (Magnetom Sonata, 
Siemens, Erlangen, Germany) using a four-element phased array cardiac receiver coil, 
and with the patient in a supine position. Scout images were acquired in the long axis 
and short axis orientations in order to specify the final short-axis views. 
To obtain the first pass contrast enhanced images a saturation prepared single shot fast 
spoiled gradient echo pulse sequence was applied (repetition time 2.0 ms, echo time 
1.0 ms, flip angle 12°, receiver band with 770 Hz/pixel, saturation delay 120 ms). The 
spatial resolution was 3-3.3 x 2.3 - 2.7 x 8 mm3, with an image matrix of 128 x 73-93. 
Perfusion scans were performed during the last minute of a 3-minute adenosine infusion 
(140 µg/kg/min) and 15 minutes later, at rest. Three short axis slices from apex to base 
at 25%, 50% and 75% of the end-systolic ventricular length were imaged. Both rest 
and stress perfusion images were acquired during breath-holding for 50 heartbeats and 
during the first pass of 0.05 mmol/kg gadolinium-based contrast agent (Magnevist, 
Schering AG, Berlin, Germany) flushed with 15 mL of 0.9% NaCL (flow rate 5 mL/s; 
Medrad, Spectris). 
During the waiting period between the stress and rest perfusion scans, ECG-gated 
cine images were acquired using a breath-hold segmented steady-state free precession 
sequence. Cine bSSFP sequence parameters were a temporal resolution of 47 ms, 
excitation angle of 60°, receiver bandwidth 930 Hz/pixel, TR/TE of 3.1/1.6 ms, matrix 
256 x 138-161 and voxel size of 1.3-1.4 x 1.8-2.0 x 5.0-6.0 mm3 .
Per patient eight to ten short-axis views were obtained every 10 mm, starting from the 
mitral valve insertion and covering the entire left ventricle. 
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Late contrast-enhanced images, in order to definitely exclude myocardial scar tissue, 
were acquired 10 minutes after the last contrast injection in the same orientation as the 
first-pass contrast enhanced images, using a 2D segmented inversion recovery spoiled 
gradient-echo pulse sequence triggered to end-diastole (repetition time/echo time = 
9.6/4.4 ms, flip angle 25°, number of excitations = 1, matrix 208 x 256, typical voxel size 
of 1.6 x 1.3 x 5.0 mm3, receiver bandwidth 130 Hz/pixel). The inversion time was set 
to null the signal of normal myocardium, and was typically in the range of 220-290 ms. 
MRI Analysis
Analysis of the MR images was done both visually and semi-quantitatively. An 
18-segment model was used, dividing the left ventricle into six basal, six midventricular, 
and six distal segments.
Qualitative assessment was by visual interpretation of the MR images by two observers. 
The SPECT and CMR analysis was performed separately. Observers of the SPECT and 
the observer of the CMR were blinded for the results of other diagnostic procedures. 
First-pass perfusion contrast-enhanced MR images were assessed for the presence or 
absence of regions of reduced contrast uptake. Delayed contrast-enhanced images 
were assessed for the presence of any hyperenhancement. The degree of myocardial 
wall thickening was assessed from functional cine images. 
Global function was assessed by calculating left ventricular end-diastolic and end-systolic 
volumes (LVEDV and LVESV, respectively) using planimetry of all short-axis images in 
each patient. Left ventricular ejection fraction (LVEF, in %) was calculated as (LVEDV – 
LVESV)/LVEDV. 
Semi-quantitative analysis was performed using a dedicated software package (Mass 
5.0, Medis, Leiden, The Netherlands). The endocardial and epicardial contours on 
perfusion images were traced, and corrected manually for cardiac motion. Each slice 
was divided into six equiangular segments, starting from the inferior septal insertion 
of the right ventricle. These segments were further subdivided into subendocardial 
and subepicardial regions, which were traced with their outer borders close to the 
endocardial and epicardial surfaces and inner borders adjacent to each other in the mid-
wall. To obtain information about the input function, an additional region was drawn 
in the left ventricular cavity. 
For each of the defined regions a curve was generated showing relative signal intensity 
plotted against time. The maximum upslopes of the myocardium and the left ventricular 
blood pool were determined using 5- and 3-point linear fits, respectively. The results for 
the myocardial regions were corrected for differences in the arterial input function of 
the contrast agent bolus by dividing the myocardial upslope by the left ventricular blood 
pool upslope (30). An index for myocardial perfusion reserve (MPRI) was calculated by 
dividing the values at maximal vasodilatation by the values at rest.
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Statistics
There was no sample size calculation. Due to the limited CMR capacity it was decided 
prior to the start of the study, to include 20 patients. For statistical analysis we used 
mean values of perfusion parameters of the subendocardial and subepicardial regions. 
In this section the summary values are presented as means ± SD. Differences between 
means in MPI and MPRI subendocardial and subepicardial of each patient were tested 
using paired student test (two-sided). A p value of less than 0.05 was considered to be 
significant. 
RESULTS
Heart rates, blood pressure and chest pain
The baseline heart rate was 71 ± 11 BPM, increasing to 94 ± 14 BPM during adenosine 
infusion. The baseline blood pressure was systolic 139 ± 20 mm Hg and diastolic 80 ± 9 
mm Hg. During maximum vasodilatation the blood pressure was systolic 140 ± 18 mm 
Hg and diastolic 73 ± 10 mm Hg. Furthermore 14 of the 20 patients experienced severe 
chest pain during adenosine infusion. The remaining 6 patients did not experience any 
chest pain.
MRI visual analysis 
All patients showed initial subendocardial signal reductions on the first pass 
cardiovascular MR images, which disappeared after approximately 5 heartbeats (see 
figure 1). This temporary signal loss is considered to be an artefact related to the 
first pass sequence and is not typical for an ischaemia related defect which shows a 
more sustained signal loss (31). These so-called dark rim artifacts were present in 93% 
of all the slice series, and in 44% of the slices series it was visible around the whole 
subendocardium.
In addition there were visual signs of ischaemia in 2 patients (in one patient a mid- 
anterior/mid-anteroseptal sustained transmural defect, and in the other a basal 
anterolateral and basal posterolateral sustained transmural defect). These signs were 
present in 4 segments out of a total of 360. In other words, only 1,1 % of the segments 
had visual signs of ischaemia. No hyperenhancement was seen on late contrast 
enhanced images.
Global ventricular function
The mean LVEDV was159 ± 35 ml, mean LVESV was 70 ± 17 ml and the mean EF was 
57 ± 3%.
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MRI semi-quantitative analysis
The myocardial perfusion index (MPI) in our study population increased significantly 
during adenosine infusion in both the subendocardium and subepicardium: from 0.091 
± 0.020 to 0.143 ± 0.030 (p<0.001), and from 0.074 ± 0.017 to 0.135 ± 0.03 (p<0.001), 
respectively, (see figure 2). Note that in both the resting and stressed states the 
subendocardial MPI was higher than the subepicardial MPI: respectively 0.091 ± 0.020 
versus 0.074 ± 0.017 (p<0.001), and 0.143 ± 0.030 versus 0.135 ± 0.03 (p=0.021). 
An index for myocardial perfusion reserve (MPRI) was calculated as the ratio of the 
MPI during stress to the MPI at rest. The MPRI for the entire transmural extent of the 
myocardium was 1.83 ± 0.50. However, there was a significant difference between 
the MPRI in the subendocardium, 1.67 ± 0.38 and the subepicardium, 1.98 ± 0.64 
(p=0.001). 
The mean subendocardial: subepicardial MPRI ratio was 0.91 ± 0.11. None of the 
patients had a subendocardial: subepicardial MPRI ratio less than 0.72, which has 
been proposed as the optimal cut-off for distinguishing between normal controls and 
subendocardial hypoperfusion in patients with syndrome X (27).
FIGURE 1: Midventricular short axis view during first pass of gadolinium during stress. Panel A 
and B show a subendocardial ring of low signal enhancement at the time of maximum signal 
enhancement in the left ventricular cavity. Serial images (C-F) show disappearance of this ring 
and subsequent homogeneous myocardial enhancement.
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DISCUSSION
This study has shown that patients with chest pain and normal coronary angiograms 
had significant perfusion responses to adenosine in both the subendocardium and 
the subepicardium. Hence, we found no evidence for subendocardial ischaemia in our 
group of patients.
The adenosine-induced significant increases in subendocardium MPI, from 0.091 to 0.143, 
contrast with an earlier MRI study, where the MPI did not change significantly (27).
These MPI values found in our patient group at rest and under stress agree with the 
results from the control group in the study by Panting et al (27). Both studies found 
significant MPI increases in the subepicardium in response to adenosine. The selection 
of both patient populations is not exactly equal, this difference in selection may partially 
explain the different results we have found in patients with syndrome X (although 
the mean age and male/female distribution were similar). In our study more patients 
with syndrome X had an abnormal myocardial SPECT result, while in the study of 
Panting et al. more patients showed an abnormal ECG during exercise. However, the 
selection of syndrome X patients using both exercise- ECG and SPECT is an accepted 
method(12). As Lanza stated in an overview exercise-induced ST segment depression 
is not required. In patients with obstructive CAD, exercise electrocardiogram may be 
negative in patients with coronary microvascular disease, whereas findings compatible 
with myocardial ischemia could be detected by other diagnostic techniques (e.g. stress 
myocardial scintigraphy)(12). 
FIGURE 2: Myocardial perfusion index in patients with syndrome X in subendocardium and 
subepicardium.
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In our study we found dark rim artefacts during the peak gadolinium concentration in 
the left ventricular blood-pool MRI images in all patients. This temporary signal loss is 
considered to be an artefact related to the first pass sequence and is not typical for 
an ischaemia related defect which shows a more sustained signal loss. These dark rims 
along parts of the subendocardial border of the left ventricle and the myocardium 
has been noticed in dynamic contrast-enhanced MR perfusion studies (31, 33). Several 
causes have been proposed for this so-called dark rim artefact, such as cardiac motion, 
Gibbs ringing due to limited spatial resolution and susceptibility. Considering the spatial 
resolution and the cardiac acquisition window applied in this study is not to be expected 
that we experienced more artifacts compared to the study of Panting et al (27). 
We found no evidence for microvascular dysfunction in the subendocardium or 
subepicardium since both regions showed a clear increase in MPI during adenosine 
infusion.
This is in accordance with previous work with PET, which failed to show absolute 
myocardial perfusion abnormalities during pharmacological stress in syndrome X 
patients compared to normal controls (4, 20). Although absolute flow determination is 
difficult with MRI, we found small differences in the MPI between the subendocardial 
and subepicardial region of the left ventricle. In the resting state there was a 21 % 
higher MPI in the subendocardium compared to the subepicardium. This result might 
be explained by the higher workload of the subendocardial part of the left ventricle 
wall, which is in agreement with an experimental study of dogs by Hittinger et al., who 
observed a 31 % ± 7 % higher blood flow in the LV subendocardium compared to the 
subepicardial region for normal dogs in the resting state (34). 
The pathogenesis of cardiac syndrome X is unclear. The main hypotheses for its 
occurrence are microvascular dysfunction or abnormal pain perception (2-4, 35). There 
have been conflicting data concerning the possible role of myocardial ischaemia in 
syndrome X. Several studies of patients with syndrome X demonstrated ischemia (1, 
15-19), while other investigations found no confirmatory evidence of ischaemia during 
stress in these patients (5, 20-22). Alternative non-ischemic mechanisms of chest pain 
have been proposed in patients with cardiac syndrome X. In one study an abnormal pain 
perception has been reported, using pain provocation by catheter movement within 
the right atrium or ventricle (36). Another study showed specific cortical activation in 
the right anterior insula in patients with syndrome X and not in controls (37). The exact 
mechanism of chest pain in patients with syndrome X remains unclear since our data do 
not support the hypothesis of subendocardial ischemia in this patient group. 
We consider the relative small number of patients and the frequent occurrence of 
subendocardial artifacts with CMR as the major study limitations.
Larger studies with newer CMR sequences and independent coronary flow measurements 
may increase the insight of subendocardial perfusion in syndrome X patients. Further 
studies are needed to reveal the cause of chest pain in this specific patient group.
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Concluding remarks
We conclude that our cardiovascular MRI study of patients with chest pain, positive 
exercise ECG stress testing and/or positive myocardial perfusion SPECT and normal 
coronary angiography, demonstrated significant adenosine-induced increases in both 
subendocardial and subepicardial myocardial perfusion indices (MPI). We found no 
evidence for specific subendocardial ischemia with MRI in this group of patients.
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Correlation of myocardial perfusion 
on cardiac magnetic resonance 
versus myocardial perfusion 
scintigraphy in cardiac syndrome X
ABSTRACT 
Background In cardiac syndrome X, which is a syndrome defined as chest pain, positive 
exercise stress testing and/or reversible myocardial perfusion defects during myocardial 
scintigraphy and normal coronary angiograms, the ischemic origin is still debated. No 
previous study compared the myocardial perfusion in stress first-pass cardiac magnetic 
resonance (CMR) versus stress single-photon emission computed tomography (SPECT) 
in cardiac syndrome X.
Methods We performed stress SPECT and CMR imaging for 20 syndrome X patients. 
Perfusion analysis of the CMR was done by using the normalized upslope of myocardial 
signal enhancement to derive the myocardial perfusion index (MPI) and the myocardial 
perfusion reserve index (MPRI). The SPECT images were visually scored by 3 observers 
using a segmental model.
Results An MPRI of £ 1.2 was found for 31 (9%) of the 335 segments, indicating 
local ischemia. SPECT indicated reversible perfusion defects for 39 (12%) of the 335 
segments. However, the combination of both an MPRI of £ 1.2 and a reversible 
perfusion defect was detected in only 3 segments. 
Conclusions Our data show about 10% stress-induced myocardial perfusion 
abnormalities on CMR and SPECT, suggesting local ischemia. However, only in 1% of 
the segments there was concordance for the presence of myocardial ischemia with 
both exams. This result may be evidence for the variability over time of the mechanisms 
responsible for coronary microvascular dysfunction. 
80
INTRODUCTION
About 20 % of patients with anginal chest pain have normal coronary angiograms 
(CAG). The term cardiac “syndrome X” was introduced to describe these patients. 
(1-3) A subgroup of these patients has objective signs of ischaemia, such as the classic 
downsloping ST-segment depression on exercise ECG testing and/or a reversible defect 
detected by myocardial Single Photon Emission Computed Tomography (SPECT). (4-9) 
The pathogenesis of this syndrome is far from clear. Different diagnostic imaging 
modalities, myocardial perfusion SPECT, cardiac Positron Emission Tomography (PET) 
and Cardiovascular Magnetic Resonance (CMR) imaging, have been used to try and 
reveal the physiological mechanism. Important results include reversible defects with 
myocardial SPECT and CMR, indicating local ischaemia. (4-6, 8, 10) Another important 
CMR finding is subendocardial ischaemia in a group of syndrome X patients. The 
ischaemia was located in the whole subendocardial layer of the left ventricle. (11) 
Subendocardial ischaemia may explain the reversible defects seen in other studies. 
However the hypothesis of subendocardial ischemia in cardiac syndrome X patients 
was not supported by our earlier CMR study done with patients having chest pain and 
normal coronary angiograms. (12) On the other hand, in that study the myocardial 
perfusion indexes (MPI) were calculated for the whole subendocardial and the whole 
subepicardial layer. Hence, regional ischaemia could have been undiscovered owing to 
averaging segmental MPI calculations as one mean subendocardial MPI and one mean 
subepicardial MPI.
To our knowledge there has not been a study comparing SPECT results and stress CMR 
results in cardiac syndrome X patients. Therefore we studied a group of patients with 
angina pectoris and normal coronary arteries using both SPECT and CMR to determine 
whether local reversible SPECT defects correlated with locally decreased myocardial 
perfusion by CMR. 
MATERIALS AND METHODOLOGY
Patient characteristics and inclusion/exclusion criteria
All 20 patients had an established (1999 – 2004) diagnosis of classic syndrome X, 
consisting of a typical history of exertional angina; an abnormal exercise electrocardiogram 
(0.1 mV horizontal or downsloping ST-segment depression of 80 msec after the J point) 
and/or a reversible perfusion defect on a myocardial SPECT; and completely normal 
findings from coronary angiography (CAG), which was independently evaluated by 
two cardiologists in separate viewing sessions and without knowledge of the clinical 
information. 
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The exclusion criteria were: percutaneous transluminal coronary angioplasty (PTCA); 
coronary artery bypass grafting (CABG) or prior myocardial infarction; spasm during 
the CAG reviewing; freedom from pain without medication; pregnancy; hypertension 
(defined as blood pressure over 140/90 mm Hg); diabetes (defined by a fasting glucose 
level above 7.8 mmol per litre or a random-sample glucose level above 11.1 mmol per 
litre); arrhythmias such as paroxysmal atrial fibrillation (PAF); left bundle branch block; 
valve dysfunction (other than mitral valve insufficiency grade 1); and abnormal left 
ventricular ejection fraction ( LVEF<50 %) or other structural abnormalities of the heart. 
Furthermore, patients having general contra-indications for CMR imaging according to 
the MR safe practice guidelines were also excluded. (13) Finally, none of the patients 
had electrocardiographic signs of left ventricular hypertrophy (defined as a value above 
35 mm for the sum of the height of the S wave in lead V1 and the height of the R wave 
in lead V5), as later confirmed by CMR. None of the patients had any
 change in clinical 
condition or medication between the investigations. 
Five patients had abnormal exercise electrocardiograms suggesting ischaemia. Eight 
patients showed an inconclusive exercise ECG test (chest pain without significant 
ST-segment depression). 
The patients received calcium-channel blockers (7 patients), nitrates (4 patients), beta-
blockers (6 patients), ACE inhibitors (1 patient), or no treatment (5 patients). These 
numbers reflect the fact that some patients received a combination of these drugs.
The study complied with the Declaration of Helsinki, was approved by the institutional 
ethics committee, and all patients gave written informed consent.
Myocardial perfusion SPECT (stress-rest 2 days protocol)
Patients were instructed to stop all cardiac medication for 2 days. The exercise was 
performed on a calibrated ergometer using a symptom-limited test with stepwise 
increased work. A 12-lead electrocardiogram and blood pressure were monitored 
throughout the entire duration. SPECT imaging was performed 45-60 minutes after 
peak exercise radiotracer injection. Day two of this study was allocated to rest. The data 
acquisition parameters were identical for the rest and stress studies.
Bull’s-eye generation with a visual analysis using a 19-segmental model was performed. 
Only 18 segments were used for comparison with the CMR. The apical segment was 
excluded because no myocardial perfusion was measured with CMR in the apical 
segment of the left ventricle.
All SPECT results were interpreted by three experienced observers, with any 
disagreements being resolved by consensus. This consensus method was used to avoid 
subjective individual SPECT results. These observers had no access to the results of the 
CMR study. Perfusion of both the stress and rest study was graded on a scale of 0 to 
4, with 0 representing normal perfusion and 4 representing a very severe perfusion 
defect. 
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CMR scan protocol (first pass stress-rest)
The patients were instructed to stop all cardiac medication and refrain from caffeine-
containing beverages 24 hours before CMR imaging, and to eat a light breakfast on 
the day of the test. Patients receiving beta-blocking drugs stopped this medication for 
at least three drug half-lifetimes. Before testing, an intravenous line of normal saline 
solution, with a 20-gauge canula, was positioned in the antecubal veins in both arms. 
We used a single canula for administration of contrast and a separate canula for the 
administration of adenosine.
Imaging was performed with a 1.5T whole body MRI scanner (Magnetom Sonata, 
Siemens, Erlangen, Germany) using a four-element phased array cardiac receiver coil, 
and with the patient in a supine position. Scout images were acquired in the long axis 
and short axis orientations in order to specify the final short axis views. 
To obtain the first pass contrast-enhanced images a saturation prepared single shot 
spoiled gradient-echo pulse sequence was applied (repetition time 2.0 ms, echo time 
1.0 ms, flip angle 12°, receiver band with 770 Hz/pixel, saturation delay 120 ms). The 
spatial resolution was 3-3.3 x 2.3 - 2.7 x 8 mm3, with an image matrix of 128 x 73-93.
Perfusion scans were performed during the last minute of a 4-minute adenosine infusion 
(140 µg/kg/min), and at rest 15 minutes later. Three short axis slices from apex to base 
at 25%, 50% and 75% of the end-systolic ventricular length were imaged. Both stress- 
and rest-perfusion images were acquired during breath-holding for 50 heartbeats and 
during the first pass of 0.05 mmol/kg gadolinium-based contrast agent (Magnevist, 
Schering AG, Berlin, Germany) flushed with 15 ml of 0.9% NaCL (flow rate 5 ml/s; 
Medrad, Spectris). 
During the waiting period between the stress- and rest-perfusion scans, ECG-gated 
cine images were acquired using a breath-hold segmented balanced steady-state free 
precession sequence (bSSFP). Eight to ten short-axis views were obtained every 10 mm, 
starting from the mitral valve insertion and covering the entire left ventricle. The cine 
bSSFP sequence parameters were a temporal resolution of 47 ms, excitation angle of 
60°, receiver bandwidth 930 Hz/pixel, TR/TE of 3.1/1.6 ms, matrix 256 x 138-161 and 
voxel size of 1.3-1.4 x 1.8-2.0 x 5.0-6.0 mm3. 
To exclude myocardial scar tissue, late contrast-enhanced images were acquired 10 
minutes after the last contrast injection and in the same orientation as the first pass 
contrast-enhanced images, using a 2D segmented inversion recovery spoiled gradient-
echo pulse sequence triggered to end-diastole (repetition time/echo time = 9.6/4.4 ms, 
flip angle 25°, number of excitations = 1, matrix 208 x 256, typical voxel size of 1.6 x 
1.3 x 5.0 mm3, receiver bandwidth 130 Hz/pixel). The inversion time was set to null the 
signal of normal myocardium and was typically in the range of 220-290 ms. 
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MRI Analysis
An 18-segment model was used, dividing the left ventricle into six basal, six 
midventricular, and six distal segments. The CMR analysis was performed separately 
from the SPECT analysis, and the CMR observer had no access to the results of the 
SPECT study and other diagnostic procedures. Delayed contrast-enhanced images were 
assessed for the presence of any hyper-enhancement. 
Semi-quantitative analysis was done using a dedicated software package (Mass 5.0, 
Medis, Leiden, Netherlands). The endocardial and epicardial contours on perfusion 
images were traced and corrected manually for cardiac motion. Each slice was 
divided into six equiangular segments, starting from the inferior septal insertion of 
the right ventricle. These segments were further subdivided into subendocardial 
and subepicardial regions, which were traced with their outer borders close to the 
endocardial and epicardial surfaces, and inner borders adjacent to each other in the 
mid-wall. To obtain information about the input function, an additional region was 
drawn in the left ventricular cavity. 
Curves showing relative signal intensity versus time were generated for each of the 
defined regions. The maximum upslopes of the myocardium and the left ventricular 
blood pool were determined using 5- and 3-point linear fits, respectively. The results for 
the myocardial regions were corrected for differences in the arterial input function of 
the contrast agent bolus by dividing the myocardial upslope by the left ventricular blood 
pool upslope (14). An index for myocardial perfusion reserve (MPRI) was calculated by 
dividing the MPI’s at maximal vasodilatation by the values at rest. Segments with an 
MPRI £ 1.2 were considered to indicate ischaemia, as in the work of Ibrahim (15)
Statistics
Following the SPECT segment scheme (but using only 18 instead of 19 segments, as 
mentioned earlier) we classified the CMR segments as non-ischaemic and ischaemic. 
Mean MPRI results were obtained for the transmural, subendocardial and subepicardial 
regions. The summary values are presented as means ± SD. Differences between 
the MPRI transmural, subendocardial and subepicardial non-ischaemic and ischaemic 
segments were tested using an unpaired student test whereby a p value of < 0.05 was 
considered significant. 
RESULTS 
Heart rates, blood pressure and chest pain
The baseline heart rate was 71 ± 11 BPM, increasing to 94 ± 14 BPM during adenosine 
infusion. The baseline blood pressure was systolic 139 ± 20 mm Hg and diastolic 80 ± 9 
84
mm Hg. During maximum vasodilatation the blood pressure was systolic 140 ± 18 mm 
Hg and diastolic 73 ± 10 mm Hg. Furthermore, 14 of the 20 patients experienced severe 
chest pain during adenosine infusion. The remaining 6 patients did not experience any 
chest pain. 
SPECT visual analysis
The SPECT results showed reversible perfusion defects in 16 patients, a mild fixed defect 
in two patients, and one reversed perfusion pattern and one normal perfusion in the 
remaining two patients. The reversible perfusion defects were found in 47 (12%) of the 
360 segments corresponding to all 20 syndrome X patients, see figure 1. 
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Figure 1: Localisation and total number of 
reversible perfusion defect segments in 20 
syndrome X patients 
SPECT
CMR analysis
No hyper-enhancement was seen on the late contrast-enhanced images. A reliable 
myocardial perfusion index (MPI) during stress and rest could be measured for 335 
(93%) of the 360 segments. MPI measurements for 25 (7%) of the segments were 
impossible owing to left ventricle outflow tract artefacts.
An index for myocardial perfusion reserve (MPRI) was calculated as the ratio of the 
MPI during stress to the MPI at rest. 31 (9.3%) of the 335 segments were assigned a 
transmural MPRI £ 1.2, indicating local ischaemia. see figure 2.
Comparison of SPECT and CMR 
Of a total of 4 reversible segments no reliable MPRI could be analysed, as it was 
planned to contain major parts of the left ventricular outflow tract (basal slice anterior 
and anterolateral). In 39 of the 335 segments also imaged by CMR (12%), a reversible 
perfusion defect was found with SPECT. 
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FIGURE 2: Localisation and total number of 
segments with a transmural Myocardial Perfusion 
Reserve Index (MPRI) £1.2 in 20 syndrome X 
patients.
MPRI of £1.2
Only 3 segments gave a matched result of a reversible perfusion defect and a transmural 
MPRI £1.2. 28 segments had a normal SPECT result combined with a low transmural 
MPRI (£1.2) (mismatch); and 36 segments had an ischaemic SPECT result combined 
with a normal CMR (mismatch). 
The summed bull’s-eye of SPECT and CMR studies of these 20 patients show a similar 
distribution of ischaemic segments throughout the left ventricle, and there was no 
specific vascular territory with a high number of ischaemic segments. Analysis showed 
there was a lack of spatial correlation between the SPECT reversible perfusion defect 
segments and the MPRI ischaemic segments in each patient. 
The mean transmural MPRI was the same in the normal and ischaemic SPECT segments 
1.85 ± 0.65 versus 1.85 ± 0.58 (p = 1). Figure 3 shows that the mean subendocardial 
MPRI values were not different in the normal and ischaemic SPECT segments (1.68 ± 
0.54 versus 1.70 ± 0.51, p = 0.860). Also, the mean subepicardial MPRI was similar in 
the normal SPECT segments versus ischaemic segments 2.01 ± 0.89 versus 2.00 ± 0.74 
(p = 0.882).
FIGURE 3: Mean subendocardial 
MPRI in the normal and ischaemic 
SPECT segments, SPECT= single-
photon emission computed 
tomography
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DISCUSSION
We found evidence for local ischaemia in 10% of the left ventricle area with both the 
CMR study and the SPECT study. However, there was no spatial match for ischaemia 
detected by SPECT and CMR for these CSX patients. Only 3 segments out of 335 
(1%) were concordant in both exams. Mismatches were present in 64 segments, 
mutually revealing ischaemia by one technique and a normal result by the other 
technique. Furthermore, SPECT-derived normal and ischaemic segments had similar 
mean myocardial perfusion reserve indexes (MPRI). In the light of these results, we 
conclude that for this group of patients local ischaemia was unlikely to be present in a 
fixed area of the left ventricle, Furthermore, it is unlikely that in this group of patients 
ischaemia was caused by a fixed anatomically or functionally abnormal vessel. On the 
other hand, the local ischaemia found with two independent techniques at different 
times could be explained by transient ischaemia. Local ischaemia might be present in a 
patient at different locations over time, a phenomenon that we speculatively describe 
as migrating ischaemia. 
These results do not necessarily conflict with our earlier analysis, in which CMR detected 
significant increases of the myocardial perfusion both in the subendocardial and 
subepicardial layer. (16) Calculation of an average MPI for the whole subendocardial 
layer may mask local ischaemia in smaller segmental area’s. Segmental analysis of the 
MPI may be more accurate than calculations of whole subendo- or subepicardial layers, 
especially since these layers will receive blood supply from different coronary vessels. 
To our knowledge this is the first study directly comparing myocardial perfusion by 
stress SPECT and CMR imaging on a segmental basis for the same cardiac syndrome 
X patients in the same territories. Our transient ischaemic findings may be consistent 
with the arguments of Maseri et al. (16) These investigators speculated that distal to 
the most constricted microvessels there could be a patchy distribution of small foci of 
ischaemia which, when confluent, might be sufficient to cause transient ST-segment 
depression and also myocardial perfusion abnormalities. (16) Some support for this 
view is provided by a study by Osamichi et al. using PET and histopathology. They 
showed extensive myocardial 18F-fluorodeoxyglucose (FDG) uptake in combination with 
irregular narrowing of the coronary microvessels at the level of capillaries as well as 
meta-arterioles in syndrome X patients. (17) Such a patchy distribution of microvascular 
dysfunction might be responsible for the segmental SPECT and CMR abnormalities in 
the present study, hence suggesting microvascular migrating or transient ischaemia in 
cardiac syndrome X patients. 
Our study is apparently partly at variance with the recent study by Lanza et al in which 
they found a relation between subendocardial perfusion defects with CMR and a 
reduced coronary flow reserve by coronary doppler in the same (anterior) region. (10) 
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However, no quantitative CMR analysis was performed. On the other hand, the Lanza 
study found reduced coronary flow reserve in the LAD coronary artery in 2 patients 
(11%) who displayed reversible perfusion defects with CMR only in the right coronary 
artery territory. This suggests a variability over time of the mechanisms responsible for 
the coronary microvascular dysfuntion (10), which is in line with our study, although in 
our population it is more frequently occurring.
Variations in the SPECT and CMR measurements in the present study may have 
contributed to the differences we found between the results of the two measurement 
techniques. This is despite our efforts to reduce the likelihood of variations and false 
positive results by using a consensus reading for the SPECT studies and a strict cut-off 
level for the MPRI calculations. For example, an MPRI of less than 1.2 indicates a clearly 
limited increase of myocardial perfusion, which is compatible with a more than 75% 
obstruction of coronary flow (15).Another potential limitation of the present study is the 
use of two different forms of stress testing for CMR and SPECT. However, for detection 
of ischaemia both types of stress testing give good results. An additional explanation 
for mismatched non-ischaemic and ischaemic segments comes from necessarily using 
the two techniques at different times. There were, however, no changes in cardiac 
medication, complaints, or changes in possible confounding factors like smoking. 
Furthermore, reversibility of anatomical changes of epicardial vessels is rather unlikely 
in patients with angina pectoris. 
With regard to the techniques themselves, we assumed that CMR would be able to 
detect more ischaemia missed by SPECT owing to the higher spatial resolution of CMR 
(18). ur results do not support this assumption, since we found a comparable percentage 
of ischaemic segments with both techniques. The accuracy of quantitative first-pass 
perfusion CMR imaging using adenosine-induced hyperaemia has been demonstrated 
in several recent studies (14, 19), and nuclear myocardial perfusion imaging with SPECT 
is widely accepted as a standard evaluation of myocardial perfusion. However, our 
comparison of CMR with SPECT may not have been optimal. For example, the apical 
segment was not assessed by CMR and was excluded from this comparison. Thus our 
study lacks a direct comparison of CMR and SPECT in the apex. Also, the segments 
used by the segmental SPECT model were somewhat larger than the segments used 
in the CMR analysis. Nevertheless, it is unlikely that the above-mentioned differences 
explain the 95% mismatch of ischaemic segments. Furthermore, studies state that first 
pass CMR and myocardial perfusion SPECT correlate well and demonstrate fair-to-good 
agreement (70–90%) in the assessment of perfusion defects. (20-23)
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CONCLUSIONS
In conclusion, our data show about 10% stress-induced myocardial perfusion 
abnormalities on CMR and SPECT, suggesting local ischaemia in cardiac syndrome X 
patients. We found no evidence for ischaemia in fixed areas of the left ventricle in 
syndrome X. We speculate that our results may be compatible and explicable with 
a coronary microvascular dysfunction that is variable over time, as recently stated by 
Lanza (10). Further studies are necessary to confirm this hypothesis.
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ABSTRACT
Background: Positron emission tomography (PET) enables robust and reproducible 
measurements of myocardial blood flow (MBF). However, the relatively limited 
resolution of PET till recently prohibited distinction between the subendocardial and 
subepicardial layers in non-hypertrophied myocardium. Recent developments in hard- 
and software, however, have enabled to identify a transmural gradient difference in 
animal experiments. The aim of the present study was to determine the feasibility 
of subendocardial and subepicardial MBF in normal human hearts assessed with 
15O-labeled water PET.
Methods: Twenty-seven healthy subjects (mean age 41 ± 13 years; 11 men) were 
studied with 15O-labeled water PET to quantify resting and hyperaemic (adenosine) MBF 
at a subendocardial and subepicardial level. In addition cardiac magnetic resonance 
imaging was performed to determine left ventricular (LV) volumes and function.
Results: Mean rest MBF was 1.46 ± 0.49 in the subendocardium, and 1.14 ± 0.342 
ml·min–1·g–1 in the subepicardium (p<0.001). MBF during vasodilation was augmented 
to a greater extent at the subepicardial level (subendocardium vs. subepicardium: 
3.88 ± 0.86 vs. 4.14 ± 0.88 ml·min–1·g–1, p=0.013). The endocardial-to-epicardial MBF 
ratio decreased significantly during hyperaemia (1.35 ± 0.23 to 1.12 ± 0.20, p<0.001). 
Hyperaemic transmural MBF was inversely correlated with left ventricular end-diastolic 
volume index (LVEDVI) ( r2=0.41, p=0.0003), with greater impact however at the 
subendocardial level.
Conclusions: 15O-labeled water PET enables MBF measurements with distinction of 
the subendocardial and subepicardial layers in the normal human heart and correlates 
with LVEDVI. This PET technique may prove useful in evaluating patients with signs of 
ischaemia due to coronary artery disease or microvascular dysfunction.
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INTRODUCTION
The subendocardium is most susceptible to perfusion impairment and ischaemia 
principally occurs in the subendocardium before advancing to the subepicardial layer.
(1) Subendocardial perfusion imaging may therefore be an important technique to 
enhance the sensitivity for detection of myocardial ischaemia. Presently, quantification 
of regional myocardial blood flow (MBF) is available with tracers such as 15O-labeled 
water (H2
15O) and positron emission tomography (PET). H2
15O PET may therefore serve 
as a tool for quantifying  impairments in microcirculatory vasodilator reactivity.(2, 3)
Recent advances in cardiac PET hard- and software  enable to distinguish between 
perfusion of the subendocardial and subepicardial layers in animal experiments and 
patients with left ventricular hypertrophy. (4, 5) However, data in normal human 
hearts are scarce. We studied the feasibility of subendocardial and subepicardial MBF 
measurements in a group of healthy volunteers using H2
15O PET during both rest and 
vasodilator stress.
METHODS
Patient population
Twenty-seven healthy subjects were studied. None of the patients had a history of 
cardiovascular disease, all were non-smokers, and none had any other cardiovascular 
risk factor. Accordingly, none of the volunteers was receiving any form of treatment. 
All underwent a physical examination, electrocardiography, laboratory analysis, and 
echocardiography revealing no abnormalities. The characteristics of the study group 
TABLE 1 Characteristics of normal subjects (n=27)
Characteristics Mean ± SD
Age (y) 41 ± 13
Sex (M/F) 11/16
LVEF (%) 61 ± 5
LVESV (ml) 71 ± 17
LVEDV (ml) 180 ± 34
Mean LV mass (g) 96 ± 24
Length (cm) 177 ± 9
Weight (kg) 74 ± 13
BSA (m2) 1.9 ± 0.2
LVEDV= left ventricular end-diastolic volume, LVEF= left ventricular ejection fraction, LVESV= left 
ventricular end-systolic volume, BSA= body surface area
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are given in Table 1. All subjects gave written informed consent, and the protocol was 
approved by the Medical Ethics Committee of the VU University Medical Centre.
Imaging protocol
PET. All scans were performed in 2D mode using an ECAT EXACT HR+ (Siemens/
CTI, Knoxville, TN, USA). The subjects were monitored constantly with single-
lead electrocardiography, and blood pressure was measured every minute. After 
a transmission scan, 1100 MBq of H2
15O was injected intravenously under resting 
conditions and subsequently during pharmacologically induced hyperaemia (adenosine, 
140 µg·kg–1·min–1), as described previously in detail.(4, 6) Emission data were corrected 
for physical decay of 15O and for dead time, scatter, randoms, and photon attenuation. 
The H2
15O emission sinograms were reconstructed using filtered back-projection with a 
Hanning filter at 0.5 of the Nyquist frequency, resulting in a transaxial spatial resolution 
of ~6.5 mm full-width at half-maximum.
Cardiac magnetic resonance (CMR) imaging. Scans were performed on a 1.5-T 
whole body scanner (Magnetom Sonata, Siemens, Erlangen, Germany) using 
a six-element phased-array radio-frequency receiver body coil. All images were 
electrocardiographically gated and acquired during repeated breath holds in mild 
expiration of 10–15s, depending on heart rate. After localization of scout scans, 
cine images were acquired with a segmented balanced steady-state free-precession 
sequence. The image parameters were as follows: 5 mm slice thickness, 5 mm slice gap, 
<50 ms temporal resolution, 3.2 ms repetition time, 1.54 ms echo time, 60° flip angle, 
and 1.3 x 1.6 mm typical image resolution. After three long-axis view cines (2-, 3-, and 
4-chamber views), a stack of 10–12 LV short-axis cines were acquired for full coverage 
of the LV).(7)
Data analysis
PET. Transaxial parametric MBF images were generated as described previously.
(8) These images were reoriented according to the anatomic axis of the heart, and 
displayed as short-axis slices. The same reslicing parameters were applied to the 
dynamic H2
15O images. Regions of interest (ROIs) on these images were defined as 
septal, anterior, lateral, and inferior walls of the LV in the basal, mid, and apical planes, 
based on the 16-segment model of the AHA/ACC.(9) Additional ROIs were defined for 
the LA and right ventricular chamber. This latter set of ROIs was projected onto the 
dynamic H2
15O images to generate image-derived input functions. The standard single-
tissue compartment model, together with these input functions, was used to determine 
MBF (ml·min–1·g–1 of perfusable tissue) for all myocardial tissue time-activity curves. 
The subendocardial and subepicardial layers were identified by dividing the myocardial 
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ROIs by a central line (Figure 1). Coronary flow reserve (CFR) was calculated as the 
ratio of hyperaemic to resting MBF. A subendocardial to subepicardial MBF ratio was 
additionally calculated. Because resting MBF is determined by cardiac workload, global 
baseline MBF corrected for the rate pressure product (RPP) was also calculated (MBF/
RPP) x 104.(10) Coronary vascular resistance (CVR) was calculated as the ratio of mean 
arterial pressure to MBF for both the subendocardial and subepicardial layers of the 
myocardium.(3)
CMR imaging. Epicardial and endocardial contours were manually drawn on all end-
diastolic (ED) and end-systolic (ES) LV short-axis images for LV volume analysis. Global 
LV function parameters, including ED Volume (LVEDV), ED volume adjusted for bsa 
(LVEDVI), ES volume (LVESV), ejection fraction (LVEF), and myocardial mass, were 
derived from epicardial and endocardial contours on the cine images by using of the 
MASS software package (Mass 5.0, Medis, Leiden, The Netherlands).
Statistics
Values are expressed as means ± SD. For comparison of two data sets, a paired or 
unpaired Student’s t-test was performed where appropriate. Multiple data sets were 
compared using multivariate ANOVA, and specific differences were identified by 
a Student’s t-test corrected for multiple comparisons with the Bonferroni inequality 
adjustment. Linear regression was used to analyze the relationships between variables. 
All analyses were performed using SPSS 14 (SPSS, Chicago, IL, USA). Significant 
differences were defined as p < 0.05.
FIGURE 1: Example of delineation of 
subendocardial and subepicardial border on 
a parametric MBF image in short axis view at 
the midventricular level.
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RESULTS
Haemodynamic parameters
Baseline heart rate was 65 ± 11, increasing to 98 ± 14 BPM during adenosine infusion 
(p<0.001). Baseline systolic blood pressure was 122 ± 15, and diastolic blood pressure 
71 ± 10 mm Hg. During maximum vasodilatation, systolic blood pressure decreased 
to 117 ± 15 and diastolic blood pressure to 64 ± 7 mm Hg (both p<0.05 vs. baseline).
Transmural MBF
Global resting transmural myocardial blood flow was 1.20 ± 0.31 and increased during 
hyperaemia to 3.94 ± 0.78 ml·min–1·g–1 (p=0.001), yielding a CFR of 3.28 ± 0.83. 
Global baseline MBF corrected for rate pressure product was 1.53 ± 0.34 ml·min–1·g–1.
Regional transmural heterogeneity
Baseline transmural MBF for anterior, lateral, inferior, septum, and segments was 
1.30 ± 0.39, 1.29 ± 0.37, 1.08 ± 0.32, and 1.11 ± 0.33 ml·min–1·g–1, respectively 
(p=0.042 by ANOVA). Hyperaemic MBF increased to 3.54 ± 0.93, 4.18 ± 0.90, 3.66 ± 
1.04, and 4.10 ± 0.96 ml·min–1·g–1 for the different regions, respectively (p=0.035 by 
ANOVA). Transmural CFR for anterior, lateral, inferior and septum segments was 2.91 
± 0.91, 3.85 ± 1.15, 3.39 ± 0.74, and 3.67 ± 1.39 (p=0.011 by ANOVA, using post hoc 
bonferroni significant difference between septum vs. anterior p=0.010).
Subendocardial vs. Subepicardial MBF
As shown in Figure 2 and listed in Table 2, the subendocardium displayed a significantly 
higher mean resting flow level of 1.46 ± 0.49 compared to the mean subepicardium 
level of 1.14 ± 0.42 ml·min–1·g–1 (p<0.001), with an endocardial-to-epicardial ratio of 
TABLE 2. Subendocardial (Endo) en subepicardial (Epi) myocardial blood flow (ml • min-1 • g-1) 
and coronary flow reserve (CFR)
Rest Hyperemia* CFR
Endo Epi p Endo / Epi Endo Epi p Endo / Epi Endo Epi p
Average 1.46±0.49 1.14±0.42 <0.001 1.35±0.23 3.88±0.86 4.14±0.88 0.013 1.12±0.20 3.14±0.83 3.97±1.04 <0.001
Anterior 1.68±0.70 1.20±0.38 <0.001 1.41±0.35 3.80±0.99 3.36±1.06† 0.020 1.22±0.48¶ 2.55±0.94 3.03±1.10‡ 0.018
Lateral 1.57±0.65 1.27±0.54 0.002 1.25±0.18 4.06±0.96 4.28±0.90 0.173 0.97±0.21 2.89±0.96 3.62±0.87 <0.001
Inferior 1.35±0.46 0.98±0.33 <0.001 1.40±0.29 3.66±1.06 3.65±1.20 0.954 1.06±0.33 3.00±1.24 4.05±1.72 <0.001
Septum 1.30±0.45 1.08±0.49 0.026 1.25±0.31 3.89±0.98 4.16±0.94 0.107 0.95±0.22 3.25±1.12 4.35±1.57 <0.001
p (ANOVA) 0.054 0.082 0.097 0.511     0.004 0.011 0.118     0.004
*p<0.001 hyperaemia versus rest for all values; † p<0.05 versus septum and lateral wall; ‡ 
p<0.05 versus septum and inferior wall; ¶ p=0.030 versus septum.
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Septum 1.30±0.45 1.08±0.49 0.026 1.25±0.31 3.89±0.98 4.16±0.94 0.107 0.95±0.22 3.25±1.12 4.35±1.57 <0.001
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FIGURE 2: Transmural, subendocardial 
and subepicardial myocardial blood flow 
(MBF) during baseline and hyperaemic 
conditions. Note, subendocardial baseline 
MBF is higher than subepicardial (1.46 
± 0.49 versus 1.14 ± 0.42 ml·min–1·g–1, 
p<0.001). In contrast, hyperaemic MBF is 
lower in the subendocardium (3.88 ± 0.86 
vs. 4.14 ± 0.88 ml·min–1·g–1, p<0.05).
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FIGURE 4: Hyperaemic transmural, 
subendocardial end subepicardial MBF 
in relation to left ventricular end-
diastolic volume index (LVEDVI).
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FIGURE 3: Endocardial-to-Epicardial 
myocardial blood flow ratio 
during baseline and hyperaemic 
conditions.  During hyperaemia, 
there was a significant reduction in 
the endocardial-to epicardial ratio 
compared to rest (rest ratio 1.35 
± 0.23 vs. stress ratio 1.12 ± 0.20 
p<0.001)
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1.35 ± 0.23. During hyperaemia, there was a significant reduction in the endocardial-to 
epicardial ratio to 1.12 ± 0.20 (p<0.001), see Figure 3. Hyperemic MBF was 3.88 ± 0.86 
in the subendocardium and 4.14 ± 0.88 ml·min–1·g–1 in the subepicardium (p=0.013). 
Hyperemic MBF increased to a greater extent at the subepicardial level compared 
with the subendocardial level, see Table 2. Baseline coronary vascular resistance (CVR) 
was 67±25 mmHg mL min-1 and 87±31 mmHg mL min-1 for the subendocardial and 
subepicardial layer, respectively. During hyperaemia CVR decreases to 22±7 mmHg mL 
min-1 and 21±5 mmHg mL min-1 respectively.
Regional subendocardial vs. subepicardial MBF
Regional analysis for rest MBF revealed significant differences between the suben-
docardial and subepicardial layer for all segments (all p<0.05). During hyperaemia PET 
was able to distinguish perfusion differences between endocardium and epicardium 
only in the anterior segment (p=0.020) in the regional analysis.
There were no differences for subendocardial MBF between the four myocardial 
segments for resting (p=0.054) or hyperaemic (p=0.511) conditions, or CFR (p=0.118). 
Subepicardial MBF was distributed homogenously during rest (p=0.082). During 
hyperaemia, however, significant differences were observed (p= 0.004) where MBF 
was lower in the anterior segment as compared with the septum (p=0.031) and lateral 
wall (p=0.009). As a consequence, CFR in the anterior wall was also lower as compared 
with the septum (p=0.004) and inferior wall (p=0.047). No regional differences in 
the endo-to-epicardial ratio between segments were observed during rest (p=0.097), 
whereas during hyperaemia the ratio was higher in the anterior wall compared with 
the septum (p=0.030).
Interrelations among PET and CMR parameters
Of the obtained PET and CMR parameters, only LVEDVI was (inversely) correlated 
to hyperaemic MBF (Figure 4). Of interest, the correlation was stronger at the 
subendocardial level as compared with the subepicardial level (p<0.05).
DISCUSSION
The ability to distinguish subendocardial from subepicardial MBF using H2
15O PET has 
been investigated and validated in previous studies. (4, 11, 12, 13) These measurements, 
however, have been restricted to patients with left ventricular hypertrophy to overcome 
the issue of partial volume effects that are caused by the relatively limited resolution of 
PET. Only recently, Rimoldi et al. have demonstrated the feasibility to detect a transmural 
perfusion gradient using H2
15O PET in an animal experiment with pigs characterized 
by comparable cardiac dimensions as normal human hearts (~ 10 mm wall thickness)
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(5). The current study extends to these observations and demonstrates that such a 
transmural perfusion gradient can similarly be detected in normal human subjects in a 
routine clinical setting with H2
15O PET.
The results show that MBF measurements in the subendocardial layer are approximately 
35% higher than in the subepicardium during resting conditions. During hyperaemia, 
augmentation of perfusion is greater at the subepicardial level and the transmural 
perfusion gradient diminishes significantly, although average subendocardial MBF 
remains approximately 10% higher. The combination of these observations led to an 
overall lower CFR in the subendocardium. These results are in line with data obtained 
from previous animal experiments where perfusion was measured with microspheres. 
Under resting conditions, subendocardial MBF is indeed consistently higher as compared 
with the subepicardial layer, with endo-to-epi flow ratios varying from ~1.1 to 1.5. (5, 
14-17) The latter observation is compatible with the fact that, under resting conditions, 
myocardial perfusion is autoregulated in response to varying metabolic demand. 
As loading conditions and, consequently, oxidative metabolism are greater in the 
subendocardial layer of the myocardium, resting perfusion will be augmented relative 
to the subepicardial layer. During hyperaemia, however, autoregulatory mechanisms 
are exhausted and myocardial perfusion is predominantly governed by intravascular 
(i.e. vascular resistance) and extravascular (i.e. diastolic perfusion time and wall stress) 
forces. (3, 18) As both intravascular and extravascular forces are increased in the 
subendocardium as compared with the subepicardial layer, a physiological transmural 
perfusion gradient drop can be observed during hyperaemia relative to resting conditions, 
as also documented in the current study. Pathophysiological conditions that are 
associated with elevated vascular resistance, irrespective of its origin, are characterized 
by a greater transmural gradient reduction and subendocardial flow frequently becomes 
even lower than subepicardial flow.(18) It is of interest to note that in the current study 
there was an inverse correlation between LVEDV and hyperaemic MBF. Although wall 
stress was not determined in these healthy subjects owing to the invasive nature of such 
measurements, according to Laplace’s law LVEDV is one of the determinants of wall 
stress and may therefore represent a physiological relationship between end-diastolic wall 
stress and hyperaemic perfusion even within the relatively small range of end-diastolic 
volumes in normal subjects. (19) The fact that this relation was more apparent at the 
subendocardial level underscores this notion as wall stress progressively declines from the 
endo to epicardial level. Moreover, the relation between hyperaemic MBF and wall stress 
has been documented in previous studies, and subendocardial hyperaemic perfusion can 
(partially) be restored by lowering end-diastolic wall stress. (4, 6, 12, 14, 20, 21)
On average, transmural resting and hyperaemic MBF values, and hence CFR, were 
comparable to a previously reported large cohort of normal subjects studied with H2
15O 
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PET.(22) Furthermore, some heterogeneity in both resting and hyperaemic MBF could 
be detected. Although these regional variations in perfusion may reflect a biological 
phenomenon, some technical consideratons must be taken into account. The model to 
quantify MBF contains an intrinsic correction for spillover from blood activity from both 
the left and right ventricular cavity, but not from adjacent tissue. This means that tissue 
surrounding the myocardium (such as the chest wall for the anterior segments, lung 
tissue for the lateral wall, and abdominal organs for the inferior wall) could influence 
perfusion values and lead to slight heterogeneity. Region definition in smaller areas 
of interest, such as with subendocardial en subepicardial flow measurements, will 
introduce more noise and potentially augment spillover artifacts from adjacent tissue. 
Moreover, spillover of activity between myocardial layers does also occur. Simulation 
models and in vivo studies have revealed that the latter will result in underestimation 
of the transmural gradient.(5, 11) 
It is therefore expected that the observed perfusion differences between layers in 
the current study will actually be even more pronounced. Another issue concerns the 
model based corrections for partial volume.(23) This correction is warranted owing to 
the relatively limited resolution of PET relative to the normal myocardial wall thickness. 
This correction is fairly robust en reproducible for transmural flow measurement, but 
might pose limitations for smaller regions comprising only half of the myocardial wall.
(24) Obviously, more studies are warranted pertaining reproducibility. Finally, but of 
paramount importance, there is the potential of cardiac and respiratory gating to further 
enhance the accuracy of subendocardial and subepicardial flow measurements. The 
current study was conducted without cardiac or respiratory gating as count statistics 
per gated frame would become insufficient for dynamic quantitative H2
15O perfusion 
imaging. Nonetheless, recent studies have clearly demonstrated that such gating 
sequences substantially improve spatial resolution.(25, 26) With the aid of list mode 
acquisition as well as time-of-flight sequences, future studies will certainly need to focus 
on the applicability of cardiac and respiratory gating to increase the spatial resolution in 
dynamic quantitative PET imaging to facilitate measurements of transmural myocardial 
perfusion gradients.(27, 28) 
Clinical implications
It seems that PET measurements of subendocardial/subepicardial flow ratio can be 
used as an index for subendocardial perfusion, using the subepicardial perfusion as 
a reference. Normal values of subendocardial perfusion and the subendocardial/
subepicardial flow ratio are of potential clinical importance for identifying patients 
at risk of subendocardial ischaemia. In a recent study a decreased subendocardial/
subepicardial flow ratio was found by PET for patients with hypertrophied hearts 
indicating microvascular dysfunction.(4) Coronary microvascular dysfunction is probably 
also the cause of the angina in a subgroup of cardiac syndrome X patients (angina-like 
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chest pain in the absence of obstructive CAD).(29, 30) Rosen et al reported however 
that no significant transmural MBF differences existed between cardiac syndrome X 
patients and controls using 15O-labeled water PET.(31) However, this does not exclude 
subendocardial ischaemia in this group of patients. (32, 33) Further studies using PET 
may reveal possible subendocardial ischemia in patients with cardiac syndrome X. 
Hence quantification of regional myocardial blood flow may be clinically useful not only 
for assessing the extent and severity of coronary vascular disease, but also to detect 
and measure impairments in microcirculatory function in non-coronary cardiac disease. 
The prognostic significance of transmural microcirculatory dysfunction in the absence 
of CAD however remains to be assessed.
CONCLUSIONS
This study demonstrates the feasibility of using 15O-labeled water positron emission 
tomography (PET) to measure myocardial blood flow in both the subendocardial and 
subepicardial layers of a left ventricle of normal thickness. This PET technique may prove 
useful in evaluating patients with signs of ischaemia due to microvascular dysfunction.
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ABSTRACT
Aims: Follow-up studies of patients with cardiac syndrome X (CSX) generally report 
good prognosis. However, some recent studies report an adverse outcome for women. 
Methods and Results: Structured literature search and meta-analysis for studies 
regarding prognosis of cardiac syndrome X patients.
We identified 85 studies, ultimately selecting 16 for inclusion. Meta-analysis yielded 
a pooled major cardiac event percentage of 1.5% per 5 years and a pooled vascular 
event percentage of 4.8% per 5 years (n=16 studies, n=1694 patients). 14 studies 
reported upon the recurrence rate of angina pectoris: the pooled percentage of angina 
recurrence is 55% (n= 1336 patients). Finally, the pooled percentage of female patients 
is 49% (n= 13 studies, n=1294 patients). 
Conclusion: The present review of recent archival literature demonstrates a pooled 
proportion of female patients of 49%. This argues against the generally accepted 
opinion and statement that CSX occurs typically or preferentially in women. The overall 
major cardiac event rate is 1.5% per 5 years. Although this is an excellent prognosis 
for CSX patients, the quality of life is impaired because of the high recurrence rate of 
angina pectoris (55%). 
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INTRODUCTION
Cardiac syndrome X (CSX) is the syndrome of angina pectoris during a positive stress 
test despite a normal coronary arteriogram. CSX is an important clinical entity(1-19). 
About 3-11% of patients undergoing coronary angiography because of typical chest 
pain have normal coronary arteries and qualify for the definition of CSX(19). 
In overviews and textbooks it is often stated that (pre-menopausal) women are 
especially prone to developing CSX. In fact, some studies concern only female patient 
populations, while others vary considerably in the proportion of women examined and 
tested. This situation needs reassessment.
Follow-up studies of patients with CSX generally report good prognosis(7, 9). However, 
a recent study reported an adverse cardiovascular outcome for women with chest pain 
and normal coronary arteries (6).
Therefore, the present paper reviews the recent literature on CSX to clarify the question 
of gender preference and discuss in detail the long-term prognosis. 
METHODS OF IDENTIFYING AND 
SELECTING THE LITERATURE
A review and meta-analysis of the literature was conducted with a comprehensive 
search of the PUBMED database to identify clinical studies on CSX that considered 
prognosis. The prognosis of CSX patients was derived from the cardiac event rate per 
year for each study and the recurrence rate of angina (when included in the studies). 
Furthermore, the gender distribution of the patient populations was considered. 
Studies were eligible for review if they met the following standardized inclusion criteria (20-22):
Full length articles; studies including CSX or patients with angina and normal coronary 
arteries; minimum number of 10 patients; studies presenting follow-up data of more 
than 2 years; and publication dates between April 1985 and February 2010.
The criteria for excluding studies were: metabolic syndrome X; studies including patients 
with near-normal coronary angiography (CAG) results; and studies of patients with 
myocardial infarction and/or cardiomyopathy were excluded.
In detail, the PubMed database was used to identify papers in which definitions and 
prognosis for CSX are described via the following terms: 
‘((Prognosis or follow up) AND ((((cardiac syndrome x OR (angina pectoris AND normal 
coronary arteries) OR microvascular angina)) AND (((“microvascular angina”[TIAB] 
NOT Medline[SB]) OR “microvascular angina”[MeSH Terms] OR cardiac syndrome 
x[Text Word]))) AND ((“syndrome x”[All] OR (((angina pectoris) OR (chest pain)) AND 
normal AND (coronary[tw] OR angiogra*[tw])) OR (microvascular angina)))) AND 
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((Humans[Mesh]) AND (English[lang]) AND (adult[MeSH])))’; with limits set to English 
language and humans.
The search strategy identified 85 studies from PUBMED. These became the source 
population for this review. The titles were screened for eligibility by one of the reviewers 
(I.V.), followed by two reviewers (I.V. and P.R.) independently assessing the abstracts 
by consensus. In this initial screening a total of 23 articles were excluded because of:
a Metabolic syndrome X, myocardial infarction and tako-tsubo cardiomyopathy 
 (14 references). 
b Non-performance of coronary angiography (2 references).
c Studies with coronary spasm (3), case report (1), antiphospholipid syndrome (1) and 
non-obstructive coronary artery disease (2) in the title. 
62 papers remained. The titles of these studies contained cardiac syndrome X (44 
papers), normal coronary arteries (14 papers) and microvascular angina (4 papers). 
The full texts of all 62 papers were retrieved for further selection, notably as to whether 
they considered prognosis. Only 17 included prognosis, but checking the references 
from all 17 resulted in another 4 papers being selected (1, 6, 12, 14). Of these remaining 
TABLE 1 cardiac syndrome X
First author year No
Average
Age (yr)
%
Men
Average
Follow-up
(yr)
Coronary event
% Rec chest 
pain
% Repeat 
CAGDeath
Myocardial
Infarction CAD
Bugiardini 1 2004 42 51.6±8.8 0 10.3 1 0 13 31 -
Chauhan 2 1993 41 46±4 39 2.9 0 0 0 64 -
Delcour 3 2009 48 60.9±12 100 7.4 0 1 5 - - 6 CVA
Foussas 4 1998 160 50.0 69 2.5 1 2 0 59 -
Fragasso 5 2009 34 56 20 14 ± 2 0 2 2 65 - 1 LV dysfunction
Gulati 6 2009 318 53.6±10.4 0 5.2 5 3 0 - - 8 CVA. 10 LV dysfunction
Kaski 7 1995 99 48.5±8 21 7±4 0 0 0 89 - 1 LV dyfunction
Lamendola 8 2008 155 58.9±10 26 11.4±6.5 0 0 3 48 21
Leu 9 2005 92 63.9±10.5 78 2.6±1.2 0 0 0 13 9 1 LV  dysfunction 3 CVA
Lichtlen 10 1995 176 48.3 65 12.4 2 4 8 81 12
Radice 11 1995 30 51±6 27 12.3±3.5 0 0 0 33 27
Scholz 12 2002 173 54±7.8 59 12.0±2.9 10 0 6 34 -
Shintani 13 2003 43 55±8 7 6.4±3.8 0 0 0 44 -
Sullivan 14 1994 138 50.0 55 2.4 0 1 0 70 -
Sun 15 2001 59 61±5 88 7.1±1.4 0 1 0 76 - 10 LV dysfunction
Suzuki 16 2002 86 59 ± 9 41 7.2 ± 3.4 0 0 0 35 2
- = non-available
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21 papers, 9 described CSX, 11 described AP and normal coronary arteries (NCA), and 
1 described microvascular angina. 
Finally, the 21 papers were independently surveyed by two authors (IV and PR) with 
respect to the definition of CSX and prognosis. This resulted in 5 papers being excluded 
as follows: an NCA study (23) also included minimal lesions of the coronary arteries 
with a reduction in diameter of less than 50%; one turned out to be only a letter(24); 
2 intervention studies did not report cardiac events (25, 26); and another appeared to 
be an intervention study of only 7 patients(27), whereas the agreed minimum number 
of patients for our review was 10. 
This survey left 16 papers for the present review. These papers covered a total of 1694 
patients. For each paper we extracted the number of patients; cardiovascular event 
rates; percentage of female/male patients (for studies including both female and male 
patients); and the percentage of patients with recurrent chest pain. In more detail:
1 Major adverse cardiac event (MACE) rates included cardiac death, myocardial 
infarction and revascularization as defined by the most recent ACC/AHA guidelines 
2010 and other studies(28-30).
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2 The vascular events included myocardial infarction, cardiac death, development 
of CAD, heart failure, and the occurrence of cerebrovascular events (http://www.
framinghamheartstudy.org/risk/gencardio.html).
3 Since some of the studies had different follow-up periods, we normalized the event 
rates to those per 5 years.
4 Before calculation of the pooled estimates of major cardiac event rates, cardiovascular 
event rates, chest pain recurrence rates and gender distribution, the heterogeneity 
of these values was tested using calculation of I2 and the Chi-square test with k-1 
degrees of freedom (k=number of studies). I2 reflects the percentage of variation 
between the studies attributable to heterogeneity rather than chance. I2 ranges 
from 0% to 100%, and values higher than 50% reflect considerable heterogeneity 
across the studies. The effects of follow-up period, gender distribution and mean 
age of the populations upon the cardiovascular event rates were studied using 
regression analysis: P values < 0.05 were considered to be significant. 
RESULTS
Table 1 lists the 16 studies included in this review. Note that (a) 2 studies did not report 
the frequency of chest pain(3, 6), (b) the follow-up period varied widely, from 2.4 years 
to 14 years, and (c) 3 studies did not have male and female patients(1, 3, 6). 
CSX prognosis
The three most important results relating to prognosis are:
1 The major cardiac event rate varied from 0 – 3.8% per 5 years, with a pooled value 
of 1.5% per 5 years (95% CI: 1 – 2.2%, n = 1694 patients), see figure 1. There was 
no significant heterogeneity between included studies regarding the major cardiac 
event rate (I2 = 37%, Chi-square 23.7, p = 0.074). The estimated annual major 
cardiac event rate was 0.3%. This includes myocardial infarction, revascularization 
and cardiovascular death, see table 1. 
2 The general cardiovascular event rate varied from 0 – 16.7% per 5 years, with 
a pooled value of 4.8% for 5 years (95% CI: 3.8 – 5.9%). However, there was 
significant heterogeneity (I2 = 79%, Chi-square 71.7, p < 0.001), see figure 2. 
3  There were 14 studies with 1336 patients for analysis of recurrent chest pain. The 
recurrence rate varied between 13.2% to 89.9% for the different study populations, 
with a pooled value of 55% (95% CI: 53 – 58% , n = 1336 patients). There was 
significant heterogeneity (Chi-square 274.9, p < 0.001), see figure 3.
The remaining results are:
4  The major cardiac event rate was not related to the length of follow-up (R2 = 0.0043), 
mean age (R2 = 0.000006) and percentage of female patients (R2 = 0.0268). 
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Shintani 0,44 (0,29 - 0,60)
Suzuki 0,35 (0,25 - 0,46)
Sun 0,76 (0,63 - 0,86)
Foussas 0,59 (0,51 - 0,66)
Lichtlen 0,81 (0,75 - 0,87)
Radice 0,33 (0,17 - 0,53)
Kaski 0,90 (0,82 - 0,95)
Chauhan 0,63 (0,47 - 0,78)
Sullivan 0,70 (0,62 - 0,78)
Bugiardini 0,31 (0,18 - 0,47)
Scholz 0,34 (0,27 - 0,42)
Leu 0,13 (0,07 - 0,22)
Lamendola 0,48 (0,40 - 0,56)
Fragrasso 0,65 (0,46 - 0,80)
Pooled percentage = 55% (53 - 58%)
0 20 40 60 80 100
percentage of patients with relapse AP
Risk relapse angina pectoris
Percentage (%)
Percentage female patients
0 20 40 60 80 100
Shintani 
Suzuki
Sun
Foussas
Lichtlen
Radice
Kaski
Chauhan
Sullivan
Scholz
Leu
Lamendola
Fragrasso
Pooled percentage = 49% (46 - 52%)
 (a) Follow-up R2 = 0.0043, y = 0.0002*x + 0.011, (b) Age R2 = 6.10-6, y = 5.10-6*x 
+ 0.0123), (c) Female percentage R2 = 0.0268, y = 6.10-5*x+0.016).
5 The total vascular cardiac event rate per study was not related to the length of 
follow-up (R2 = 0.0011), mean age ( R2 = 0.238) and percentage of female patients 
(R2 = 0.063). 
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 (a) Follow up R2 = 0.0011, y = 0.0005*x + 0.0484, (b) Age R2 0.2376, y = 0.00042*x 
+ 0.1793, (c) Female percentage R2 = 0.063, y = 0.0004 *x + 0.0758).
6 There were 13 studies available for possible gender differences. The percentage of 
female patients ranged from 11.9% to 93.0%, with a pooled percentage of 49.2% 
(95% CI: 46.5% – 52.0%), n = 1294 patients), see figure 4.
DISCUSSION
CSX gender distribution
The proportion of women in the 16 studies included in this review varied considerably, 
ranging from 0.12 to 1.0, with a pooled estimate of 0.49. Thus we conclude that there 
is no significant gender preference with respect to CSX. 
It is generally accepted (e.g. in authoritative textbooks) that the majority of CSX patients 
are women. Some authors, as in the WISE study, have even suggested that CSX is a 
women’s disease(6). The systematical review data do not support the assumption or 
suggestion that CSX is a women’s disease, since 51% of the population was male. 
Potential pathophysiological explanations based on gender, such as estrogen depletion, 
obviously apply to only part of the population(31, 32). 
A wealth of recent evidence from patients referred for coronary angiography notes 
more frequent non-obstructive CAD in women than in men. Women with extensive 
CAD have a higher mortality than men with the same condition. Moreover, the extent 
of non-obstructive CAD, as measured by coronary computed tomographic angiography, 
predicts mortality in women but not in men. This led Shaw to hypothesize that a 
gender-specific pathobiological process, responsible for atherosclerotic disease, could 
explain the difference(33). Be that as it may, this difference is important for the CSX 
gender discussion: there could be two different types of CSX, warranting different 
diagnostic and therapeutic strategies for each gender. This possibility requires further 
investigation.
Overall cardiac event rates
This systematic review shows that the CSX prognosis in terms of the overall cardiac 
event rate is excellent, with a risk upon myocardial infarction or cardiovascular death 
of 1.5% per 5 years. The Framingham Heart Study reported annual hard (death, 
myocardial infarction) coronary event rates of 1.2% (men < 65 years); 2.7% (men > 65 
years); 0.5% (women < 65 years); and 1.6% (women > 65 years). These rates are all 
higher than the major adverse cardiac event (MACE) rate for CSX patients determined 
from our systematic review.
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The lower cardiac event rates for CSX patients suggest that they may benefit from 
protective factors against coronary macrovascular disease. These factors could be (a) 
cardioprotective medication, (b) a healthier lifestyle to avoid angina and myocardial 
infarction, e.g. becoming non-smokers, and (c) another biological mechanism. A possible 
example of the latter is the observation that platelet reactivity decreases after stress 
in patients with CSX, in contrast to patients with coronary artery disease (CAD)(34, 
35). On the other hand, the better prognosis of CSX patients compared to the general 
population may result from a selection process. CSX patients all have, by definition, 
normal coronary arteries, which is not necessarily the case in the general population. 
The difference in prevalence of coronary atherosclerosis between CSX patients and the 
general population may explain the difference in cardiac event rates. 
The notion of the benign nature of CSX has been challenged by reports of a high risk 
of future cardiac events in patients with angina and normal coronary arteries(1, 36, 
37). A recent study, named the Women’s Ischaemia Syndrome Evaluation (WISE) study 
involved 540 symptomatic women referred for coronary angiography and followed 
up for a mean of 5.2 years. The control group was asymptomatic, and consisted of 
community-based age- and race-matched women with no history of heart disease, and 
who were followed up for 10 years.
The WISE study showed a cardiovascular event rate of 7.9% per 5 years for women 
with angina and normal coronary arteries (CSX), compared to 2.4% per 5 years for the 
asymptomatic control group(6). The WISE study CSX event rate lies outside the 95% 
confidence interval of 3.8% – 5.9% per 5 years that we found from our reviewed studies. 
However, the rate of cardiovascular death was not significantly different between de 
CSX women and the control (asymptomatic) women in the WISE study. The increased 
cardiovascular event rate in symptomatic women with normal coronary arteries was 
largely accounted for by an increased incidence of hospitalisation for heart failure 
and stroke. It remains unexplained why the incidence of heart failure and stroke are 
increased in this specific population, although microvascular dysfunction might precede 
macrovascular atherosclerosis. 
CSX and non-obstructive CAD cardiac event rates
It is important to distinguish between CSX, with normal coronary arteries, and non-
obstructive CAD (19). The cardiac event rate for CSX patients is significantly better 
than that for patients with angina and non-obstructive CAD. This is illustrated by Sicari 
(38), who reported that a subgroup of patients with angina and non-obstructive CAD 
(incorrectly identified as CSX), and with positive dipyridamole echocardiography tests, 
had a survival rate of only 76% after 7.1 years follow-up. 
Five year cardiac event rates for cardiovascular events were significantly different for 
three subgroups in the WISE study: 16% per 5 years for women with angina and non-
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obstructive CAD (stenosis <50%); 7.9% per 5 years for women with angina and normal 
coronary arteries (CSX); and 2.4% per 5 years for the asymptomatic control group (P 
≤ 0.002)(6). Hence, in this large study a higher incidence of events in symptomatic 
women with non-obstructed CAD was found compared with patients with symptoms 
and normal coronary arteries. 
CSX and coronary microvascular dysfunction (CMVD)
Lanza recently proposed to rename CSX as stable primary coronary microvascular 
dysfunction (CMVD)(39). This proposal was made on the premise that abnormalities 
in the coronary microcirculation are the probable cause of CSX ischaemia and angina. 
However, Herzog obtained contemporary positron emission tomography (PET) data 
that suggest an increased cardiac event rate for patients with microvascular dysfunction, 
irrespective of abnormalities in the epicardial coronary arteries(40). (Note: this study 
was not included in our literature review because CAGs were not performed.)
In the study by Herzog the patients with a reduced flow reserve, defined as a CFR < 
2.0, had a higher annual cardiac event rate and a higher risk of cardiac death, and this 
included patients with a normal perfusion PET (40). Specifically, a subgroup of patients 
with normal perfusion but impaired CFR had a significantly higher major annual cardiac 
event rate (6.25%) compared to patients with a normal CFR (1.4%). Also, the annual 
cardiac death rate was higher: 3.1% for patients with normal perfusion but impaired 
CFR, compared to 0.5% for patients with normal CFR. Thus it is possible for patients 
with a normal perfusion, who therefore are unlikely to have epicardial coronary 
obstructive disease, to already have a reduced CFR, and that this is associated with a 
higher cardiac event rate or higher risk of cardiac death. The reduced CFR was most 
likely caused by microvascular or endothelial dysfunction(40). Therefore one should be 
cautious about equating CSX (which has a generally good prognosis) with coronary 
microvascular dysfunction,
Limitations to the significance of the study by Herzog are (a) the relatively small number 
of patients in the subgroup with normal perfusion and impaired CFR (n = 32), and (b) 
that after 10 years follow-up the impaired CFR could not predict any cardiac event in 
this subgroup(40). Hence larger prospective studies are needed. Be that as it may, 
we may conclude that a distinguishing diagnosis between CSX and CMVD requires 
evaluation of the distal compartment (intramural arterioles) as well as the proximal 
compartment (the large epicardial coronary arteries).
Recurring chest pain 
As stated earlier, recurrence of chest pain occurred in an average of 55% of the CSX cases 
included in our systematic review. In the study by Lantinga, 85% had at least weekly 
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episodes of chest pain up to 1 year after the angiograms, with the pain unchanged or 
even worse; and 33% underwent at least one more coronary angiography(41).
The most important therapy consists of reassurance, risk factor modification, and 
symptom relief (ACC/AHA guidelines 2002, www.acc.org/qualityandscience/clinical/
statements.htm). There are conflicting data about the exact cause of chest pain 
in patients with CSX, There is evidence for ischaemia (17, 42), and alternatively, 
psychological factors like an increased anxiety may play a role in CSX (18). The number 
of pain episodes can be reduced by beta-blockers, calcium antagonists, nitrates and 
imipramine, which is particularly successful(43). Similar success has been claimed for 
estrogen replacement therapy(31, 32). In a patient with coronary spasms we found an 
increase of the myocardial blood flow and decrease of symptoms using bosentan, an 
endothelin receptor antagonist(44). However, the therapeutic measures remain largely 
empirical, and the symptoms persist in many patients.
LIMITATIONS 
Systematic reviews are hampered by publication bias, i.e., the preferential publication 
of studies with significant positive results rather than those with negative results. 
However, in studies regarding prognosis and survival this phenomenon is probably less 
frequent compared to studies evaluating therapeutic strategies. 
Another potential problem is that clinical prognostic studies are almost inevitably 
different in their length of follow-up, which can affect the study results because longer 
follow-up periods might yield more exact prognostic figures. However, in our review we 
found no relation between the length of follow-up and event rates.
There are possible limitations owing to varying inclusion criteria for the different 
studies. These variations can cause heterogeneous meta-analysis results. For example, 
we found in earlier work that there were more than 50 different criteria (nine different 
inclusion criteria and forty-three different exclusion criteria) for CSX, resulting in a 
varying reported incidence of CSX(19). Also, the heterogeneity of the different study 
populations may have contributed to the heterogeneity that we found with respect to 
the prognoses from the studies.
On the other hand, the advantages of reviews and meta-analyses are an increase in 
statistical power, the ability to assess sources of heterogeneity, and the provision of 
overall estimates of prognostic variables. 
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CONCLUSIONS
The present review of recent archival literature on CSX demonstrates no clear gender 
differences for the incidence of CSX, in contrast to the general assumption or suggestion 
that CSX is a women’s disease. This systematic review found an overall major adverse 
cardiac event rate of 1.5% per 5 years. This represents a better prognosis compared to 
the general population. However, angina pectoris in CSX is recurrent and persistent in 
55% of the patients, and significantly impairs the quality of life. 
Whether CSX patients benefit from protective factors against acute coronary events is 
a challenging issue that should be addressed in future studies. The possibility that there 
are two types of CSX, related to gender, should also be investigated.
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9Chapter
9 Summary

SUMMARY
A significant number of patients with angina pectoris and a positive stress test for 
ischaemia are found to have normal coronary arteries. This combination of symptoms 
and (apparent) circulatory normality is called cardiac syndrome X (CSX). Patients with 
CSX can experience much physical and mental distress and significant restrictions to 
leading a normal life.
Chapter 1 is the introduction of the thesis and gives the summary of the proposed 
pathophysiologic explanation for CSX. Two mechanisms that are not mutually 
exclusive have been proposed: myocardial ischemia that might be caused by coronary 
microvascular dysfunction and enhanced sensitivity to intracardiac pain or the so-called 
“sensitive heart” syndrome. Secondly, the problem about incidence of CSX including 
the various test characteristics of non-invasive stress test was described. Finally, gender 
differences of angina and CSX are discussed. 
Chapter 2 reviews the literature (2003-2008) on the definition and incidence of CSX, 
using a standardized search strategy. We included 57 articles. Nine different inclusion 
criteria and forty-three exclusion criteria were found in the 57 articles. When these 
inclusion and exclusion criteria were applied to a sample population with normal 
coronary angiograms, treated during one year at a general hospital, the attributable 
CSX incidence varied between 3% (AP, positive stress test and normal CAG) and 11% 
(so-called ‘broad diagnosis’ CSX). This variation is considerable and shows that there is 
a need for a generally accepted definition of CSX. Contrasting study results may be due 
to these different applied inclusion characteristics. An additional aspect of the review, 
discussed also in Chapter 8, was to assess the often-proposed gender differences of 
CSX occurrence. 
Chapter 3 is a case history of patient with coronary spasms. Many of these patients 
suffer from persistent chest pain despite optimal medical treatment, and it has been 
suggested that patients with coronary spasm have a disturbance in the endothelial 
function of their coronary arteries. We used 15O-labeled H2O PET to assess myocardial 
perfusion and response to endothelin-receptor antagonist treatment. We measured an 
impaired coronary flow reserve (CFR) in 6 of 13 segments directly before the start of 
bosentan therapy. A repeated PET measurement after 16 weeks of bosentan treatment 
revealed a completely normalized CFR. Furthermore, the patient reported less frequent 
and less severe chest pain. Our data suggest a potential role of endothelin-receptor 
antagonists for patients with severe and persistent coronary vasospasms. 
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Chapter 4 investigates the possible link between anxiety and ischaemia in CSX 
patients, whereby we obtained independent measurements of anxiety levels and the 
extent of ischaemia. The patients were screened with both the Trait and State Scales of 
the State-Trait Anxiety Inventory (STAI), and they all underwent myocardial perfusion 
scintigraphic imaging. Patients with a low trait anxiety had significantly less ischemic 
segments on the myocardial perfusion imaging than patients with a high trait anxiety 
(1.8 ± 1.9 vs. 3.5 ± 0.6, p<0.05). For state anxiety no significant differences could 
be found. These results showed that CSX patients with high trait anxiety are at risk 
of having more extended ischemia compared to CSX patients with low trait anxiety. 
This suggests that anxiety-induced ischemia can occur in CSX patients, and that high 
trait anxiety might be a predisposing risk factor for microvascular dysfunction and/or 
ischaemia causing reversible perfusion defects on the SPECT imaging of CSX patients.
Chapter 5 describes the use of first-pass perfusion cardiac magnetic resonance (CMR) 
to semi-quantitatively assess subendocardial and subepicardial myocardial blood flow 
in 20 CSX patients. As hypothesized, and already described by a single CMR study, 
subendocardial hypoperfusion might be present in CSX patients. In our CMR investigation 
a myocardial perfusion index (MPI) was calculated using the normalized upslope of 
myocardial signal enhancement. An index for myocardial perfusion reserve (MPRI) was 
calculated by dividing the MPI values at maximal vasodilatation by the values at rest. The 
MPI in our study population increased significantly during adenosine infusion in both the 
subendocardium (from 0.091 ± 0.020 to 0.143 ± 0.030: p<0.001) and the subepicardium 
(from 0.074 ± 0.017 to 0.135 ± 0.03: p<0.001).  Both the resting and stressed states the 
subendocardial MPI was higher than the subepicardial MPI: respectively 0.091 ± 0.020 
versus 0.074 ± 0.017 (p<0.001), and 0.143 ± 0.030 versus 0.135 ± 0.03 (p=0.021). There 
was a significant difference between the myocardial perfusion reserve index (MPRI) in 
the subendocardium, 1.67 ± 0.38 and the subepicardium, 1.98 ± 0.64 (p=0.001).   The 
mean subendocardial: subepicardial MPRI ratio was 0.91 ± 0.11. None of the patients 
had a subendocardial: subepicardial MPRI ratio less than 0.72, which has been proposed 
as the optimal cut-off for distinguishing between normal controls and subendocardial 
hypoperfusion in patients with syndrome X.
We found no evidence for subendocardial hypoperfusion in patients with syndrome X.
However, on our first-pass CMR images we found initial dark rim artefacts in the 
subendocardium in all patients. This temporary signal loss is considered to be an 
artefact related to the first pass sequence and is not typical for an ischaemia related 
defect which shows a more sustained signal loss. Our results support the idea that 
these artefacts have been mistaken for subendocardial hypoperfusion by Panting et al. 
Chapter 6 investigates the correlation between stress CMR and single photon emission 
computed tomography (SPECT) imaging, using regional flow analysis instead of global 
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MBF evaluation for 20 CSX patients. This investigation was to check the hypothesis 
that focal ischaemia occurs in relatively small myocardial regions scattered throughout 
the myocardium. Both the CMR and SPECT data showed in about 10% of all segments 
stress-induced myocardial perfusion abnormalities, which would appear to suggest focal 
ischaemia and patchy distributions. Of course, on the other hand, these differences 
might be related to possible false results of non-invasive techniques. Interestingly, the 
stress induced perfusion abnormalities were found in different regions of the CMR and 
SPECT images of the same patients. Due to the time delay between the CMR and SPECT 
stress tests the regional mismatch of the CMR and SPECT results, may be the result 
of transient focal ischaemia. We did not demonstrate a regional match of ischaemia 
between CMR and SPECT studies, this makes microvascular dysfunction in certain fixed 
coronary territories unlikely. If microvascular dysfunction is associated with ischaemia in 
CSX patients it may not be an irreversible pathophysiological phenomenon but rather 
a temporary malfunction or dysregulation. Hence, subclinical atherosclerosis may be 
compatible with transient focal ischaemia in CSX patients. 
But if microvascular dysfunction is the case in CSX, the abnormality may not involve all 
coronary microvessels of a major coronary branch uniformly, but may be distributed in 
a patchy scattered manner. CAG only detects epicardial lesions and is unable to obtain 
objective evidence for this kind of myocardial ischaemia. Hence, our results could be 
due to the time-dependent variability of the mechanisms responsible for microvascular 
dysfunction, i.e. due to so-called transient ischaemia. 
Chapter 7 gives the results of cardiac PET measurements of subendocardial and 
subepicardial myocardial blood flow in normal healthy controls. Since PET measurements 
of transmural myocardial blood flow with 15O-labeled water are currently the gold 
standard, the technique can be used as a tool to assess subendocardial ischaemia 
in patient populations. However, only very limited data are available regarding 
subendocardial and subepicardial MBF measurements with 15O-labeled water PET, 
and data in normal controls are lacking. In the present study a population of 27 
subjects was included without angina pectoris and a mean age of 41 years. Mean rest 
MBF was 1.46 ± 0.49 in the subendocardium, and 1.14 ± 0.342 ml·min–1·g–1 in the 
subepicardium (p<0.001). Stress MBF during adenosine increased to a greater extent at 
the subepicardial level (subendocardium vs. subepicardium: 3.88 ± 0.86 vs. 4.14 ± 0.88 
ml·min–1·g–1, p=0.013). The endocardial-to-epicardial MBF ratio decreased significantly 
during hyperaemia (1.35 ± 0.23 to 1.12 ± 0.20, p<0.001). Hyperaemic transmural 
MBF was inversely correlated with left ventricular end-diastolic volume index (LVEDVI) 
(r2=0.41, p=0.0003), with greater impact at the subendocardial level.
 15O-labeled water PET enables MBF measurements with distinction of the subendocardial 
and subepicardial layers in the normal human heart and correlates with LVEDVI. This 
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PET technique may prove useful in evaluating patients with signs of ischaemia due to 
coronary artery disease or microvascular dysfunction. 
Finally, chapter 8 reviews the prognosis of CSX, which is generally reported as good, 
although a recent study reported an adverse outcome for women. Furthermore, it is 
stated that (pre-menopausal) women are prone to develop CSX, and some studies 
are focused only upon female patients. The objective of this review and meta-analysis 
was to evaluate the risk of a major cardiac event and the risk of persistent symptoms 
in different CSX patient populations. Additionally, we determined the existence and 
extent of the predominance of women in CSX patient populations. Sixteen studies, 
comprising a total of 1694 patients, met the inclusion criteria and were included in the 
review.  With respect to CSX prognosis, it turns out that the overall major cardiac event 
rate for CSX patients is 1.5% per 5 years. This represents a better prognosis compared 
to the general population, suggesting that CSX patients may benefit from protective 
factors against coronary macrovascular disease. However, because angina pectoris 
in CSX is recurrent and persistent in 55% of the patients, it represents a significant 
impairment of the quality of life. With respect to gender, our review demonstrated that 
the pooled proportion of female CSX patients is 49%. This argues against the generally 
accepted opinion and statements that CSX occurs typically or preferentially in women. 
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Conclusions and Future 
Perspectives

CONCLUSIONS AND FUTURE 
PERSPECTIVES
‘Chest pain with normal coronary angiograms: is the heart innocent or guilty?’ is the 
title of a review paper (1) in 1990 by Cannon (Bethesda, Maryland). Cannon’s recent 
paper ‘microvascular angina and the continuing dilemma of chest pain with normal 
coronary angiograms’ summarizes the current knowledge on the pathophysiology, 
diagnosis and management of cardiac syndrome X (CSX) (2). Most important, in his 
opinion, remains the need for advanced imaging technology to resolve the mechanism 
that links coronary microvascular dysfunction to myocardial ischaemia 
Mental stress and endothelial dysfunction
In the present thesis we found a relation between anxiety and the extent of ischaemia 
in CSX patients. 
The atherogenic effect of anxiety is becoming increasingly clear, as a recent long-term 
study by Janszky (3) showed. This study involved nearly 50,000 young Swedish men 
between the ages of 18 and 20 years, with a follow-up of 37 years. It was found that 
anxiety, as diagnosed according to ICD-8 criteria, provided independent predictions of 
coronary heart disease.
With regard to the pathophysiology of CSX this phenomenon of ‘mental stress 
ischaemia’ may be an important contributor to microvascular dysfunction. Mental 
stress, especially anxiety, causes endothelial dysfunction (via endothelin-A receptors) 
and results in atherosclerosis (4). 
Looking to the future, there are two possible studies that readily come to mind:
(1) A randomized, controlled trial investigating the possible influence of anxiety-
regulating mind-body therapy (autogenic training, tai chi) on CSX. Such a trial 
could provide more insight into the pathophysiology of stress-induced ischaemia 
in CSX patients, especially if it were combined and compared with the scanning of 
patients deliberately subjected to mental stress. 
(2) A randomized intervention trial using an endothelin-receptor antagonist. Endothelial 
dysfunction is frequently described in CSX patients, and our limited data suggest a 
potential role of endothelin-receptor antagonists for patients with severe coronary 
vasospasms. An endothelin-receptor antagonist study is best done using cardiac 
PET to measure the MBF.
 
These studies could be extended with an adenosine stress study that includes 
measurements of the sCD40 ligand. This possibility was recently suggested by 
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Kaski (St. George University of London, and a world authority on CSX) because the 
sCD40 molecule is inflammatory and could play a role in the pathogenesis of CSX. 
Furthermore, Kaski suggested that oestrogen depletion might also play a pathologic 
role in endothelial dysfunction in CSX. This suggestion arises from Kaski’s focus on peri- 
or postmenopausal women.  
In more detail, Kaski considers that abnormal pain perception may contribute to the 
genesis of CSX, and that oestrogen plays an important part in the pain perception. 
Oestrogen receptors are expressed in cells of the cardiovascular system and modulate 
vasomotor tone as a result of a rapid vasodilator effect. Furthermore, changes in 
women’s oestrogen concentrations modulate the natural ability of the brain to suppress 
pain. When oestrogen values are high, the brain’s natural anti-nociceptive system 
responds in a stronger fashion to painful stimuli, releasing endorphins than dampen the 
pain signals received by the brain. When oestrogen is low, the system does not control 
pain as efficiently. The consequence is that low oestrogen levels are associated with 
endothelial dysfunction and an impaired function of the natural endogenous opioid 
system, resulting in increased pain perception. 
Kaski recommends studying short-term oestrogen therapy in larger cohorts, before 
individual patients start long-term oestrogen medication. From the above considerations 
it is possible that oestrogen therapy might reduce anginal episodes and improve 
myocardial blood flow. More generally, Kaski advises a multidisciplinary approach that 
involves cardiologists, general physicians, pain units and psychologists, together with 
prone ‘hot’ lines or internet ‘clinics’ to reduce unnecessary hospital re-admissions.
Future imaging technology for diagnosing CSX
Today CAG is a necessary step in the diagnosis of patients suspected to have CSX. This 
diagnostic method outlines the lumina of the coronary arteries and can be used to 
exclude significant coronary obstruction.  However, CAG provides no information about 
the arterial wall, and severe atherosclerosis that does not encroach on the lumen may 
go undetected. Therefore myocardial perfusion imaging (e.g. PET) will be mandatory 
in the future. 
Other disadvantages of CAG are the complications. This invasive test carries a 1 in 1000 
risk of stroke or myocardial infarction; and there are other problems such as transient 
tachy- or bradyarrhythmias, or bruising or bleeding at the catheter insertion site, 
although these problems occur in less than 1% of patients. Finally, the contrast agents 
can provoke side effects like hypotension, nausea, a warm sensation, and transient 
deterioration of renal function. 
In this light, non-invasive structural imaging like Coronary CT angiography (CTA) might 
be of interest. In the diagnostic work-up of coronary artery disease the emerging 
capabilities of CT imaging compete with many other well-established and readily 
available diagnostic modalities. However, CT imaging is prone to artefacts, because 
138
it stretches the temporal and spatial resolution of CT scanners. The artefacts include 
those due to motion, which typically blurs the contours of the coronary arteries. Also, 
the partial volume in CT leads to overestimating the dimensions of high-intensity 
objects (e.g. calcification within coronary arteries) and may cause difficulties in image 
interpretation (5). The technology of cardiac CT will continue to progress. Whereas 
radiation exposure sets a limit to increases in spatial resolution, temporal resolution will 
likely be increased considerably, thereby reducing the artifacts. Careful clinical studies 
of appropriate size and design will be needed to clarify the role of coronary CTA in CSX. 
Although CTA cannot presently be considered a routine replacement for invasive 
coronary angiography, it is conceivable that CTA in combination with positron emission 
tomography (PET) will be clinically applied to rule out coronary stenoses in patients 
suspected of having CSX. Hybrid imaging of CTA with PET is rapidly emerging. Cardiac 
CTA/PET allows quantification of cardiac perfusion in combination with assessment of 
coronary anatomy within a single scanning session of less than 45 minutes. The important 
technical advantages of PET compared to SPECT (e.g. the attenuation correction, the 
high spatial resolution, and high extraction fraction of the ideal PET tracers) result in 
a sensitivity and specificity of 92-93%. The low radiation burden is another important 
advantage. The near-simultaneous anatomical evaluation of coronary arteries using CT 
and their corresponding functional status using PET provide a wealth of complementary 
information about patients being evaluated for suspected CSX (5). 
Patients with AP, abnormal stress test and normal CAG are a common occurrence for 
all cardiologists. Using the CSX incidence data of a general hospital in 2003 it can be 
assumed there are about 5000 new CSX patients in the Netherlands per year. Hence, 
a cardiologist has a limited experience with CSX patients. 
A standard diagnostic work-up of CSX patients in CSX expertise centres could be useful 
for further studies. More specifically, CSX expertise centres with larger populations of 
CSX patients than seen in general hospitals may make intervention studies possible, for 
example a psychological treatment or an interventional medical therapy combined with 
advanced imaging technology (e.g. cardiac gated PET-CT, gated PET-MRI).
Since advanced imaging technology may be necessary, such ‘CSX centres of excellence’ 
would have state-of-the-art equipment, like cardiac gated PET-CT or gated PET-MRI. 
For example, microvascular dysfunction is best detected in the subendocardium, since 
ischaemia nearly always begins there. Subendocardial ischaemia has been described in 
CSX patients (6), although in our study we found no evidence of it. Hence further studies 
with cardiac PET (with 15O-labelled water or 82Rb) or MRI may be necessary to detect 
possible subendocardial ischaemia in CSX patients. Also, quantitative measurements of 
both the subendocardial and the subepicardial myocardial blood flow would enable an 
objective evaluation of potential new therapies.
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Finally, we suggest (a) further research into subendocardial perfusion in CSX patients 
using 15O-labelled water 4D-gated PET/CT; (b) multicentre studies in combination with 
current best practice; and (c) the development of professional guidelines for diagnosis 
and treatment of CSX. 
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Ongeveer 20% van alle patiënten die een hartkatheterisatie (CAG) ondergaan wegens 
pijn op de borst, hebben normale kransslagaderen. Wanneer er bij deze patiënten ook 
tekenen zijn van zuurstoftekort van de hartspier, zoals een positieve inspanningstest of 
een positieve hartscan, wordt gesproken van cardiaal syndroom X (CSX).
Hoewel de prognose van deze patiënten goed is, beperken de heftige recidiverende 
thoracale pijnklachten het dagelijkse leven van deze patiënten. Dit leidt tot herhaalde 
ziekenhuisopnamen, arbeidsongeschiktheid en een grote psychische belasting.
Hoofdstuk 1
Hoofdstuk 1 is de introductie van dit proefschrift en geeft een samenvatting van de 
mogelijke oorzaken van cardiaal syndroom X. Enerzijds zou een grotere gevoeligheid 
voor pijn, het zogenaamde “hypersensitieve hart”, een rol kunnen spelen. Anderzijds 
worden aanwijzingen gevonden voor zuurstof tekort van de hartspier (myocard), 
veroorzaakt door het niet goed functioneren van de kleinste bloedvaten (haarvaten), 
coronaire microvasculaire dysfunctie genoemd. 
In de introductie wordt eveneens de controverse rondom de diagnose CSX beschreven. 
In de literatuur zijn er verscheidene criteria voor het stellen van de diagnose CSX. Dit 
leidt tot heterogene studiegroepen. Daarnaast is het belangrijk te realiseren dat geen 
enkele niet-invasieve stresstest perfect is. 
Tenslotte wordt er ingegaan op interraciale en sekseverschillen. 
Hoofdstuk 2
Er zijn geen exacte cijfers bekend over hoe vaak syndroom X voorkomt. Daartoe hebben 
we retrospectief onderzocht hoeveel patiënten we gedurende 1 jaar tegenkwamen 
in een groot perifeer ziekenhuis in Nederland. Voorts bespreken we middels een 
gestandaardiseerde zoekstrategie de verschillende gehanteerde CSX definities in de 
literatuur (periode 2003-2008). We identificeerden uiteindelijk 57 artikelen (totaal 
aantal patiënten: n=2375), die de basis vormden voor dit review. Deze 57 studies 
toonden veel variatie in de gehanteerde criteria voor de diagnose CSX: 9 verschillende 
inclusiecriteria en 43 verschillende exclusie criteria. Afhankelijk van de gehanteerde 
definitie vonden we een incidentie variërend van 3% tot 11% van alle CAG patiënten. 
Gezien het grote effect van de verschillende definities op de incidentie van CSX, blijkt 
dat er een noodzaak is aan een uniforme definitiestelling voor cardiaal syndroom X. 
Daarnaast vonden wij in het review dat slechts een kleine meerderheid van de CSX 
patiënten vrouw is. CSX lijkt dus geen typische vrouwenziekte te zijn, wat vaak wordt 
beweerd in studieboeken en overviews.
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Hoofdstuk 3
Hoofdstuk 3 beschrijft een ziekte geschiedenis van een patiënt met coronaire spasmen. 
Veel van deze patiënten hebben last van hardnekkige pijn op de borst, ondanks 
optimale medische behandeling. Enkele studies hebben gesuggereerd dat patiënten 
met coronaire spasmen een verstoring in de endotheliale functie van de kransslagaderen 
hebben. We hebben deze patiënt 16 weken met de endotheline-receptor antagonist 
bosentan behandeld. Positron emissie tomografie (PET) met gebruik van radioactieve 
tracers zoals zuurstof-15-gelabeld water maakt het mogelijk myocardperfusie te 
meten in absolute zin. Het effect van de bosentan behandeling hebben wij middels 
PET gemeten. Direct vóór de aanvang van behandeling met bosentan maten wij 
een verminderde doorbloeding na farmacologische stress in 6 van 13 segmenten in 
het hart. De herhaalde PET meting na 16 weken bosentan behandeling toonde een 
volledig genormaliseerd perfusie na stress. Bovendien vertelde patiënt minder frequent 
en minder ernstig pijn op de borst klachten te ondervinden tijdens de bosentan 
therapie. Deze resultaten zouden kunnen wijzen op een rol van endotheline-receptor 
antagonisten bij patiënten met coronaire vasospasmen.
Hoofdstuk 4 
Het zuurstoftekort van de hartspier in CSX patiënten zou o.a. veroorzaakt kunnen 
worden door mentale stress zoals angst. We hebben in dit hoofdstuk het mogelijke 
verband tussen angst en ischemie in CSX patiënten onderzocht. De patiënten werden 
gescreend op angst middels de gevalideerde State-Trait Anxiety Inventory (STAI). 
Daarnaast ondergingen alle patiënten een myocardperfusiescan. Patiënten met een 
lage angstdispositie hadden aanzienlijk minder zuurstoftekort op de hartscan, dan 
patiënten met een hoge angstdispositie (1,8 ± 1,9 versus 3,5 ± 0,6, p <0,05). De aanleg 
om angstig te zijn is een risicofactor voor de uitgebreidheid van het zuurstoftekort van 
de hartspier bij CSX patiënten.
Deze bevindingen suggereren dat angst-geïnduceerde ischemie kan optreden bij CSX 
patiënten. 
Hoofdstuk 5 
Hoofdstuk 5 beschrijft een cardiale MRI (CMR) studie welke de hartspier van patiënten 
met CSX in meer detail bestudeert. Algemeen wordt gedacht dat de binnenste helft 
van de hartspier (‘subendocardiale deel’) eerder een zuurstoftekort heeft in vergelijking 
met de buitenste helft (‘subepicardiale deel’) van het hart. Cardiale MRI maakt het 
mogelijk deze twee delen te bestuderen. De hypothese was dat CSX veroorzaakt zou 
worden door verminderde perfusie in de binnenzijde van de hartspier na stress, zoals 
beschreven in één eerdere CMR studie.
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Middels CMR werd de myocard perfusie index (MPI) zowel in rust als in stress 
(adenosine) gemeten, alsmede de index voor myocard perfusie reserve (MPRI), in zowel 
de subendocardiale als subepicardiale laag van het hart. 
Er was een goede en gelijkwaardige perfusie toename in stress in onze studie populatie 
in zowel het subendocard als in het subepicardium. 
We vonden geen bewijs voor subendocardiale hypoperfusie bij patiënten met het 
syndroom X.
Hoofdstuk 6 
In hoofdstuk 6 wordt de correlatie tussen CMR en myocardscan Single Photon Emission 
Computed Tomografie (SPECT) onderzocht in CSX patiënten. 
In dit onderzoek wordt specifieker naar de regionale doorbloeding gekeken. Bij de 
eerdere studie werd gekeken naar de globale doorbloeding van de subendocardiale en 
subepicardiale laag. Hierbij wordt geen rekening gehouden met potentiële regionale 
verschillen in doorbloeding. Gezien het feit dat drie verschillende kransslagaderen de 
doorbloeding van de linker harthelft verzorgen is een regionale analyse van belang. 
De linker zijde van het hart wordt hierbij onderverdeeld in 19 segmenten, volgens de 
richtlijnen van American Heart Association.
De hypothese was dat de ischemie in CSX heel focaal in kleine gebieden verspreid 
in het hart optreedt. Zowel de CMR als de SPECT scans toonden in ongeveer 10% 
van alle segmenten ischemie. Echter de locatie van de ischemie kwam in beide 
onderzoeken niet met elkaar overeen. Deze mismatch zou kunnen worden veroorzaakt 
door voorbijgaande focale ischemie. De microvasculaire dysfunctie is dan blijkbaar 
niet gerelateerd aan een vaste kransslagader, maar kan wisselen. Natuurlijk kunnen 
onze bevindingen ook vals-positief voor ischemie zijn, inherent aan elke niet-invasieve 
beeldvormende test. Echter de ‘gouden standaard’ hartkatheterisatie (CAG) brengt 
alleen de epicardiale kransslagaderen in beeld. Onderzoeken waarbij de doorbloeding 
van de hartspier wordt bestudeerd (bijv. met SPECT of MRI) kunnen beïnvloed worden 
door afwijkingen in de kransslagaderen (zichtbaar te maken met de CAG) maar ook 
door afwijkingen in de kleine vaten (zogenaamde microvasculaire dysfunctie). De CAG 
kan microvasculaire dysfunctie niet detecteren, zodat de CAG slechts ten dele geldt als 
een gouden standaard voor onderzoeken die de hartspier doorbloeding meten. 
Hoofdstuk 7 
Positron emissie tomografie (PET) met gebruik van zuurstof-15-gelabeld water is 
momenteel de gouden standaard voor het meten van transmurale myocard perfusie in 
absolute zin. Ischemie begint meestal aan de binnenzijde van het hart (subendocard). 
Het is dus belangrijk om een techniek te ontwikkelen welke de absolute perfusie 
in het subendocard kan meten. Er zijn in de literatuur enkele studies bekend welke 
subendocardiaal en subepicardiale perfusie metingen middels PET hebben verricht, 
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echter perfusiemetingen in normale controle personen ontbreken. Hoofdstuk 7 
beschrijft de zuurstof-15-gelabeld water PET studie, welke de subendocardiale en de 
subepicardiale perfusie meet in 27 gezonde proefpersonen. In rust was de perfusie 
1,46 ± 0,49 in de subendocard, en 1,14 ± 0,342 ml · min-1 · g-1 in het subepicardium 
(p <0,001). Tijdens stress neemt de perfusie in het subepicard meer toe vergeleken 
met het subendocard.  Zuurstof-15-gelabeld water PET maakt perfusie metingen met 
onderscheid tussen de subendocardium en subepicardium mogelijk in het normale 
menselijke hart. Deze PET-techniek kan in de toekomst nuttig zijn in de diagnostiek van 
patiënten verdacht voor zowel primaire (CSX) als secundaire microvasculaire dysfunctie.
Hoofdstuk 8
Hoofdstuk 8 bespreekt de prognose van patiënten met CSX. In studieboeken en 
in overviews wordt gesteld dat de prognose van CSX goed is. Echter recentelijk 
rapporteerde een studie een negatieve uitkomst voor vrouwen met angina pectoris 
en normale kransslagaders. In dit review wordt de prognose beschreven. Zestien 
studies (totaal 1694 patiënten) voldeden aan de inclusie criteria. De kans op een major 
cardiac event zoals een myocard infarct, dood door hart-en vaatziekte of noodzaak 
tot revascularisatie voor CSX patiënten is 1,5% per 5 jaar. Dit zou kunnen betekenen 
dat CSX patiënten zelfs een betere prognose hebben in vergelijking met de algemene 
bevolking. De angina pectoris blijft echter in 55% van alle patiënten bestaan. Hoewel de 
prognose van deze patiënten dus goed is, beperken de heftige recidiverende thoracale 
pijnklachten het dagelijks leven van deze patiënten.
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TOEKOMST PERSPECTIEVEN
Voor de evaluatie van de kransslagaders is de hartkatheterisatie essentieel. Aangezien 
patiënten met CSX normale kransslagaders hebben, is de hartkatheterisatie ook 
noodzakelijk om de diagnose CSX te stellen. Er wordt veel onderzoek verricht naar niet-
invasieve technieken die belangrijke epicardiale stenosen kunnen uitsluiten en idealiter 
tegelijkertijd microvasculaire dysfunctie kunnen opsporen. 
Niet-invasieve cardiale beeldvorming, zoals coronaire CT-angiografie (CTA) is sterk 
in ontwikkeling. Hoewel CTA (momenteel) niet kan worden beschouwd als een 
routinematige vervanging voor de invasieve coronaire angiografie, is het denkbaar dat 
CTA in combinatie met positron emissie tomografie (PET) in de toekomst bij patiënten 
verdacht voor CSX kan worden toegepast. De bijna gelijktijdige anatomische evaluatie 
van de kransslagaderen middels CTA en de bijbehorende kwantificatie van de perfusie 
verkregen met de PET geeft veel informatie in een totale onderzoeksduur van slechts 
45 minuten. 
In de toekomst is nog veel ontwikkeling te verwachten van nieuwe PET tracers, zoals 
radioliganden voor de endotheline-receptor, de angiotensine II type 1 receptor en het 
adrenerge systeem, evenals vooruitgang in de cardiale PET software and hardware 
technologie, zoals de gated PET en de combinatie van PET met MRI. 
De introductie van gated PET/CTA of PET/MRI maakt onderzoek naar subendocardiale 
perfusie, oa. bij patiënten met verdenking op CSX, met behulp van zuurstof-15-gelabeld 
water potentieel betrouwbaarder.
Verder zou het wenselijk zijn om in de toekomst de zorg rondom CSX te verbeteren. 
Evenals in vooraanstaande centra (University of Bologna, Instituta Cardiologica Roma, 
St. George’s Hospital London, Chicago, Hammersmith Hospital London, Brigham and 
Women’s Hospital Boston, Cedar-Sinai Medical Center, Los Angeles) moet gekozen 
worden voor een multidisciplinaire benadering, waar oa. de psychologie niet kan 
worden gemist.
Waar het gaat om het wetenschappelijk onderzoek en de ontwikkeling van evidence 
based richtlijnen moet gestreefd worden naar (inter)nationale samenwerking.
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Prof. dr. Emile Comans, Dr. Bart van Berckel, Dr. Jan Roos, Dr. Rik Pijpers, Annelies van 
Schie, Dr. Corneline Hoekstra, Reiny Kooistra, Mohammed Akkariou, Joris Tim, Nafees 
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om met jullie te werken in de VU.
Prof. A. Lammertsma, Dr. Ronald Boellaard, Dr. Mark Lubberink, Dr. Arthur van Lingen, 
Amanda Kroonenberg-Kalwij, Jaap van der Kuij, Reina Kloet, Saskia Cornielje en alle 
MNW’ers en medewerkers NG-PET veel dank voor jullie ondersteuning.
Dr. P. Knaapen, beste Paul, jouw passie voor het vak tezamen met je uitgebreide kennis, 
maakten het heel uitdagend om met jou te discussiëren. 
Dr. A.M. Beek, O. Bondarenko, M Belderok, beste Aernout, Olga en Mary, ondanks jullie 
drukke schema’s maakten jullie tijd voor mijn CSX patiënten. Dank voor de bijdragen 
aan de CMR studies.
Beste Dr. Olivier Temmerman, Dr. Bas Holverda en Bart Wittgen, door de jaren heen 
hebben jullie mij semilegaal voorzien van veel software, vergezeld van nuttige tips en 
grapjes. Dank daarvoor.
Dr. Pieter Willem Kamphuisen, je belde ons vanuit het AMC met een klinisch probleem, 
gevolgd door prettige emails, uiteindelijk resulterend in ons case report. Misschien dat 
mijn promotie de gelegenheid is om nu eens kennis te maken?
Beste Ingrid Riphagen, wat een werk waren al die losgekoppelde referenties. Dank!
Alle medewerkers van het Verbeeten Instituut, in het bijzonder Arjan van Dijk, Gerard 
Tijmes en Thed Naber, dank voor jullie interesse, ondersteuning en de tijd die ik kreeg 
om mijn proefschrift af te ronden. 
Mijn ooms, tantes, neven, nichten, vrienden, vriendinnen. Hartelijk dank voor alles wat 
helemaal niets met dit onderzoek te maken had!
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Mijn paranimfen Ilona, dierbare vriendin en Koen, oudste broer, fijn dat jullie naast me 
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Mijn zus Pit, broers Nard en Koen, schoonouders, schoonzussen en zwagers, dank voor 
de gezelligheid, steun en interesse.
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Abbreviations

ABBREVIATIONS
Abbreviations used in this thesis are:
AP: angina pectoris
CAD: coronary artery disease
CAG: coronary angiography
CBF: coronary blood flow
CFR: coronary flow reserve
CMR: cardiac magnetic resonance
CMVD: coronary microvascular dysfunction
CSX: cardiac syndrome X
ECG: electrocardiography
LV: left ventricular
LVEDV: left ventricular end-diastolic volume
LVEDVI: left ventricular end-diastolic volume index
LVESV: left ventricular end-systolic volume
LVEF: left ventricular ejection fraction
MACE: major adverse cardiac event
MBF: myocardial blood flow
MPI: myocardial perfusion index
MPRI: myocardial perfusion reserve index
NCA: normal coronary arteries
PET: positron emission tomography
SPECT: single photon emission computed tomography
STAI: state-trait anxiety inventory
VSMC: vascular smooth muscle cells
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